Cannabinoid   O   O
administration   O   O
reduced   O   O
DMN   O   O
hyperconnectivity   O   O
and   O   O
increased   O   O
DMN-ECN   O   O
anticorrelation   O   O
.   O   O
Moreover   O   O
,   O   O
the   O   O
magnitude   O   O
of   O   O
anticorrelation   O   O
in   O   O
the   O   O
controls   O   O
,   O   O
and   O   O
in   O   O
the   O   O
patients   O   O
after   O   O
cannabinoid   O   O
administration   O   O
,   O   O
positively   O   O
correlated   O   O
with   O   O
WM   O   O
performance   O   O
.   O   O
The   O   O
finding   O   O
that   O   O
DMN   O   O
brain   O   O
connectivity   O   O
is   O   O
plastic   O   O
may   O   O
have   O   O
implications   O   O
for   O   O
future   O   O
pharmacotherapeutic   O   O
development   O   O
,   O   O
as   O   O
treatment   O   O
efficacy   O   O
could   O   O
be   O   O
assessed   O   O
through   O   O
the   O   O
ability   O   O
of   O   O
therapies   O   O
to   O   O
normalize   O   O
underlying   O   O
circuit-level   O   O
dysfunction   O   O
.   O   O
Experimental   StudyMethod   ModifiedMiniMentalState
Materials   StudyMethod   ModifiedMiniMentalState
and   StudyMethod   ModifiedMiniMentalState
Methods   StudyMethod   ModifiedMiniMentalState
Subjects   O   O
Twelve   O   O
patients   Schizophrenia   FullScaleIntelligenceQuotient
with   Schizophrenia   FullScaleIntelligenceQuotient
SCZ   Schizophrenia   FullScaleIntelligenceQuotient
and   O   O
CUD   CannabisAbuse   O
and   O   O
twelve   O   O
healthy   NoKnownDisorder   ControlSubject
control   NoKnownDisorder   ControlSubject
subjects   NoKnownDisorder   ControlSubject
participated   O   O
in   O   O
this   O   O
study   O   O
.   O   O
As   O   O
previously   O   O
described   O   O
in   O   O
all   O   O
patients   O   O
were   O   O
recruited   O   O
from   O   O
community   O   O
mental   O   O
health   O   O
centers   O   O
and   O   O
met   O   O
criteria   O   O
for   O   O
SCZ   Schizophrenia   O
and   O   O
CUD   CannabisAbuse   O
,   CannabisAbuse   O
defined   CannabisAbuse   O
as   CannabisAbuse   O
either   CannabisAbuse   O
current   CannabisAbuse   O
cannabis   CannabisAbuse   O
abuse   CannabisAbuse   O
or   CannabisAbuse   O
dependence   CannabisAbuse   O
with   CannabisAbuse   O
use   CannabisAbuse   O
within   CannabisAbuse   O
the   CannabisAbuse   O
past   CannabisAbuse   O
month   CannabisAbuse   O
prior   CannabisAbuse   O
to   CannabisAbuse   O
study   CannabisAbuse   O
enrollment   CannabisAbuse   O
,   O   O
as   O   O
determined   O   O
by   O   O
the   O   O
Structured   StructuredClinicalInterviewforDSMDisorders   StructuralImaging
Clinical   StructuredClinicalInterviewforDSMDisorders   O
Interview   StructuredClinicalInterviewforDSMDisorders   O
for   StructuredClinicalInterviewforDSMDisorders   O
DSM-IV-TR   StructuredClinicalInterviewforDSMDisorders   O
(   StructuredClinicalInterviewforDSMDisorders   O
SCID   StructuredClinicalInterviewforDSMDisorders   O
)   StructuredClinicalInterviewforDSMDisorders   O
.   O   O
While   O   O
a   O   O
history   O   O
of   O   O
alcohol   O   O
or   O   O
substance   O   O
use   O   O
(   O   O
other   O   O
than   O   O
cannabis   O   O
)   O   O
was   O   O
permitted   O   O
in   O   O
the   O   O
patient   O   O
group   O   O
,   O   O
they   O   O
were   O   O
required   O   O
to   O   O
be   O   O
alcohol   O   O
and   O   O
substance   O   O
free   O   O
for   O   O
a   O   O
minimum   O   O
of   O   O
seven   O   O
days   O   O
prior   O   O
to   O   O
testing   O   O
and   O   O
scanning   O   O
.   O   O
Tobacco   O   O
users   O   O
were   O   O
included   O   O
in   O   O
the   O   O
study   O   O
,   O   O
since   O   O
up   O   O
to   O   O
90%   O   O
of   O   O
patients   O   O
with   O   O
SCZ   O   O
smoke   O   O
cigarettes   O   O
.   O   O
All   O   O
patients   O   O
were   O   O
on   O   O
a   O   O
stable   O   O
dose   O   O
of   O   O
antipsychotic   O   O
medication   O   O
for   O   O
a   O   O
minimum   O   O
of   O   O
one   O   O
month   O   O
prior   O   O
to   O   O
study   O   O
participation   O   O
.   O   O
Patients   O   O
taking   O   O
clozapine   O   O
were   O   O
excluded   O   O
given   O   O
its   O   O
proposed   O   O
ability   O   O
to   O   O
decrease   O   O
alcohol   O   O
and   O   O
cannabis   O   O
use   O   O
in   O   O
patients   O   O
with   O   O
SCZ   O   O
.   O   O
Pharmacotherapies   O   O
for   O   O
addiction   O   O
,   O   O
mental   O   O
retardation   O   O
,   O   O
a   O   O
history   O   O
of   O   O
head   O   O
injury   O   O
,   O   O
or   O   O
factors   O   O
that   O   O
contraindicate   O   O
the   O   O
use   O   O
of   O   O
fMRI   O   O
served   O   O
as   O   O
exclusion   O   O
criteria   O   O
.   O   O
The   NoKnownDisorder   O
healthy   NoKnownDisorder   AlternativeHealthyEatingIndex2010
control   NoKnownDisorder   O
group   NoKnownDisorder   O
was   O   O
matched   O   O
to   O   O
the   O   O
patient   O   O
sample   O   O
on   O   O
age   O   O
,   O   O
gender   O   O
and   O   O
handedness   O   O
.   O   O
In   O   O
addition   O   O
to   O   O
the   O   O
exclusion   O   O
criteria   O   O
noted   O   O
above   O   O
,   O   O
controls   O   O
were   O   O
excluded   O   O
if   O   O
they   O   O
had   O   O
any   O   O
current   O   O
or   O   O
history   O   O
of   O   O
Axis   O   O
I   O   O
or   O   O
II   O   O
disorders   O   O
,   O   O
including   O   O
any   O   O
substance   O   O
use   O   O
disorder   O   O
.   O   O
A   O   O
signed   O   O
informed   O   O
consent   O   O
was   O   O
obtained   O   O
from   O   O
participants   O   O
prior   O   O
to   O   O
initiation   O   O
of   O   O
the   O   O
study   O   O
.   O   O
The   O   O
protocol   O   O
was   O   O
approved   O   O
by   O   O
the   O   O
Committee   O   O
for   O   O
the   O   O
Protection   O   O
of   O   O
Human   O   O
Subjects   O   O
(   O   O
IRB   O   O
)   O   O
at   O   O
Dartmouth   O   O
College   O   O
.   O   O
Further   O   O
details   O   O
of   O   O
the   O   O
study   O   O
design   O   O
were   O   O
reviewed   O   O
in   O   O
.   O   O
Study   StudyMethod   O
Design   StudyMethod   StudyDesign
and   StudyMethod   StudyDesign
Procedure   StudyMethod   O
Participants   O   O
refrained   O   O
from   O   O
substance   O   O
use   O   O
(   O   O
except   O   O
for   O   O
tobacco   O   O
or   O   O
caffeine   O   O
)   O   O
for   O   O
the   O   O
duration   O   O
of   O   O
the   O   O
study   O   O
.   O   O
Subjects   O   O
completed   O   O
a   O   O
‘   O   O
baseline   O   O
’   O   Depression
session   O   Depression
(   O   O
T1   O   O
)   O   O
,   O   O
and   O   O
then   O   O
returned   O   O
one   O   O
week   O   O
later   O   O
for   O   O
a   O   O
second   O   O
scan   O   O
session   O   O
(   O   O
T2   O   O
)   O   O
during   O   O
which   O   O
patients   O   O
were   O   O
randomized   O   O
to   O   O
one   O   O
of   O   O
two   O   O
double-blinded   O   O
cannabinoid   O   O
intervention   O   O
groups   O   O
:   O   O
an   O   O
oral   O   O
THC   O   O
group   O   O
(   O   O
N   O   O
=   O   O
6   O   O
)   O   O
or   O   O
an   O   O
active   O   O
cannabis   O   O
cigarette   O   O
(   O   O
3.6%   O   O
THC   O   O
)   O   O
group   O   O
(   O   O
N   O   O
=   O   O
6   O   O
)   O   O
.   O   O
Those   O   O
in   O   O
the   O   O
THC   O   O
group   O   O
were   O   O
given   O   O
a   O   O
15mg   O   O
THC   O   O
pill   O   O
(   O   O
three   O   O
hours   O   O
prior   O   O
to   O   O
scanning   O   O
)   O   O
and   O   O
then   O   O
smoked   O   O
a   O   O
placebo   O   O
cannabis   O   O
cigarette   O   O
immediately   O   O
prior   O   O
to   O   O
scanning   O   O
.   O   O
Those   O   O
in   O   O
the   O   O
cannabis   O   O
group   O   O
were   O   O
given   O   O
a   O   O
placebo   O   O
pill   O   O
(   O   O
3   O   O
hours   O   O
prior   O   O
to   O   O
scanning   O   O
)   O   O
and   O   O
then   O   O
smoked   O   O
an   O   O
active   O   O
3.6%   O   O
THC   O   O
cannabis   O   O
cigarette   O   O
immediately   O   O
before   O   O
scanning   O   O
.   O   O
Smoking   O   O
took   O   O
place   O   O
in   O   O
a   O   O
smoking   O   O
chamber   O   O
within   O   O
the   O   O
scanner   O   O
bay   O   O
,   O   O
immediately   O   O
prior   O   O
to   O   O
scanning   O   O
(   O   O
Figure   O   O
1a   O   O
)   O   O
.   O   O
Patients   O   O
who   O   O
were   O   O
tobacco   O   O
smokers   O   O
were   O   O
asked   O   O
to   O   O
smoke   O   O
a   O   O
cigarette   O   O
90   O   O
minutes   O   O
prior   O   O
to   O   O
scanning   O   O
,   O   O
based   O   O
upon   O   O
pharmacokinetics   O   O
of   O   O
smoked   O   O
tobacco   O   O
.   O   O
Further   O   O
details   O   O
can   O   O
be   O   O
found   O   O
in   O   O
.   O   O
Healthy   NoKnownDisorder   O
control   NoKnownDisorder   ControlSubject
participants   NoKnownDisorder   O
followed   O   O
the   O   O
same   O   O
study   O   O
protocol   O   O
,   O   O
but   O   O
did   O   O
not   O   O
receive   O   O
any   O   O
pharmacologic   O   O
intervention   O   O
during   O   O
T2   O   O
.   O   O
In   O   O
order   O   O
to   O   O
assist   O   O
patients   O   O
in   O   O
remaining   O   O
abstinent   O   O
from   O   O
substance   O   O
use   O   O
for   O   O
the   O   O
duration   O   O
of   O   O
the   O   O
study   O   O
,   O   O
they   O   O
were   O   O
assessed   O   O
three   O   O
times   O   O
in   O   O
the   O   O
week   O   O
prior   O   O
to   O   O
each   O   O
scan   O   O
session   O   O
.   O   O
Each   O   O
time   O   O
,   O   O
they   O   O
were   O   O
screened   O   O
for   O   O
substance   O   O
use   O   O
with   O   O
an   O   O
alcohol   O   O
breathalyzer   O   O
,   O   O
a   O   O
Timeline   SubstanceUseScale   O
Follow-Back   SubstanceUseScale   O
interview   SubstanceUseScale   O
,   O   O
and   O   O
a   O   O
urine   O   O
toxicology   O   O
screen   O   O
(   O   O
ToxCup   O   O
Drug   O   O
Screen   O   O
cup   O   O
;   O   O
CLIAwaived   O   O
,   O   O
Sand   O   O
Diego   O   O
,   O   O
CA   O   O
)   O   O
.   O   O
Patients   O   O
were   O   O
discontinued   O   O
from   O   O
the   O   O
study   O   O
if   O   O
screening   O   O
suggested   O   O
substance   O   O
use   O   O
during   O   O
study   O   O
participation   O   O
.   O   O
THC   O   O
and   O   O
symptom   O   O
measures   O   O
Venous   O   O
blood   O   O
samples   O   O
were   O   O
collected   O   O
from   O   O
patients   O   O
at   O   O
T1   O   O
,   O   O
in   O   O
the   O   O
morning   O   O
of   O   O
the   O   O
T2   O   O
session   O   O
,   O   O
immediately   O   O
prior   O   O
to   O   O
fMRI   FunctionalMagneticResonanceImaging   O
scanning   FunctionalMagneticResonanceImaging   O
,   O   O
and   O   O
before   O   O
cognitive   O   O
testing   O   O
(   O   O
Figure   O   O
1b   O   O
)   O   O
.   O   O
The   O   O
Marijuana   SubstanceCravingScale   CocaineCravingQuestionnaire_BriefVersion
Craving   SubstanceCravingScale   CocaineCravingQuestionnaire_BriefVersion
Questionnaire   SubstanceCravingScale   CocaineCravingQuestionnaire_BriefVersion
(   SubstanceCravingScale   CocaineCravingQuestionnaire_BriefVersion
MCQ   SubstanceCravingScale   CocaineCravingQuestionnaire_BriefVersion
)   SubstanceCravingScale   CocaineCravingQuestionnaire_BriefVersion
,   O   CocaineCravingQuestionnaire_BriefVersion
Cannabis   SubstanceCravingScale   CocaineCravingQuestionnaire_BriefVersion
Withdrawal   SubstanceCravingScale   CocaineCravingQuestionnaire_BriefVersion
Scale   SubstanceCravingScale   CocaineCravingQuestionnaire_BriefVersion
(   SubstanceCravingScale   CocaineCravingQuestionnaire_BriefVersion
CWS   SubstanceCravingScale   CocaineCravingQuestionnaire_BriefVersion
)   SubstanceCravingScale   CocaineCravingQuestionnaire_BriefVersion
,   O   O
and   O   O
Positive   PositiveandNegativeSyndromeScale   PositiveandNegativeSyndromeScale
and   PositiveandNegativeSyndromeScale   PositiveandNegativeSyndromeScale
Negative   PositiveandNegativeSyndromeScale   PositiveandNegativeSyndromeScale
Syndrome   PositiveandNegativeSyndromeScale   PositiveandNegativeSyndromeScale
Scale   PositiveandNegativeSyndromeScale   PositiveandNegativeSyndromeScale
(   PositiveandNegativeSyndromeScale   PositiveandNegativeSyndromeScale
PANSS   PositiveandNegativeSyndromeScale   PositiveandNegativeSyndromeScale
)   PositiveandNegativeSyndromeScale   PositiveandNegativeSyndromeScale
were   O   O
administered   O   O
to   O   O
assess   O   O
for   O   O
change   O   O
in   O   O
marijuana   O   O
craving   O   O
,   O   O
withdrawal   O   O
,   O   O
and   O   O
positive   O   O
and   O   O
negative   O   O
symptoms   O   O
.   O   O
Change   O   O
in   O   O
these   O   O
measures   O   O
was   O   O
analyzed   O   O
using   O   O
repeated   O   O
measures   O   O
analysis   O   O
of   O   O
variance   O   O
(   O   O
ANOVA   O   O
)   O   O
with   O   O
group   O   O
as   O   O
the   O   O
between   O   O
group   O   O
factor   O   O
and   O   O
time   O   O
as   O   O
the   O   O
within-subjects   O   O
factor   O   O
,   O   O
followed   O   O
by   O   O
post-hoc   O   O
analysis   O   O
using   O   O
Tukey   O   O
’   O   O
s   O   O
LSD   O   O
test   O   O
for   O   O
pairwise   O   O
comparisons   O   O
.   O   O
Working   O   O
memory   O   O
performance   O   O
To   O   O
assess   O   O
for   O   O
change   O   O
in   O   O
working   O   O
memory   O   O
performance   O   O
induced   O   O
by   O   O
cannabis   O   O
and   O   O
THC   O   O
,   O   O
the   NeurocognitiveTest   O
Wechsler   NeurocognitiveTest   DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
Adult   NeurocognitiveTest   DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
Intelligence   NeurocognitiveTest   DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
Scale   NeurocognitiveTest   DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
(   NeurocognitiveTest   DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
WAIS   NeurocognitiveTest   DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
)   NeurocognitiveTest   DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
III   NeurocognitiveTest   O
Letter   NeurocognitiveTest   O
Number   NeurocognitiveTest   O
Sequencing   NeurocognitiveTest   O
Test   NeurocognitiveTest   O
was   O   O
administered   O   O
approximately   O   O
30   O   O
minutes   O   O
after   O   O
the   O   O
end   O   O
of   O   O
the   O   O
scanning   O   O
sessions   O   O
at   O   O
T1   O   O
and   O   O
T2   O   O
.   O   O
This   O   O
test   O   O
was   O   O
selected   O   O
because   O   O
of   O   O
availability   O   O
of   O   O
alternate   O   O
forms   O   O
and   O   O
thus   O   O
its   O   O
applicability   O   O
to   O   O
the   O   O
repeated-measures   O   O
study   O   O
design   O   O
.   O   O
The   O   O
change   O   O
in   O   O
WM   O   O
performance   O   O
in   O   O
patients   O   O
was   O   O
evaluated   O   O
with   O   O
a   O   O
repeated-measures   O   O
ANOVA   O   O
.   O   O
A   O   O
correlation   O   O
analysis   O   O
between   O   O
WM   O   O
performance   O   O
and   O   O
the   O   O
magnitude   O   O
of   O   O
DMN-ECN   O   O
anticorrelation   O   O
was   O   O
performed   O   O
between   O   O
the   O   O
MPFC   O   O
component   O   O
of   O   O
the   O   O
DMN   O   O
and   O   O
the   O   O
DLPFC   O   O
component   O   O
of   O   O
the   O   O
ECN   O   O
.   O   O
fMRI   FunctionalMagneticResonanceImaging   Thing
data   FunctionalMagneticResonanceImaging   O
acquisition   FunctionalMagneticResonanceImaging   O
fMRI   FunctionalMagneticResonanceImaging   StudyData
data   FunctionalMagneticResonanceImaging   StudyData
were   O   O
obtained   O   O
using   O   O
a   O   O
3T   O   O
Phillips   O   O
Achieva   O   O
fMRI   O   O
scanner   O   O
with   O   O
an   O   O
8   O   O
channel   O   O
head   O   O
coil   O   O
.   O   O
Each   O   O
subject   O   O
underwent   O   O
two   O   O
8   O   O
-   O   O
minute   O   O
resting   RestingStateImaging   O
scans   RestingStateImaging   O
during   O   O
the   O   O
study   O   O
with   O   O
eyes   O   O
open   O   O
,   O   O
one   O   O
at   O   O
baseline   O   O
(   O   O
T1   O   O
)   O   O
,   O   O
and   O   O
the   O   O
second   O   O
during   O   O
the   O   O
‘   O   O
intervention   O   O
’   O   O
session   O   O
(   O   O
T2   O   O
)   O   O
.   O   O
Further   O   O
details   O   O
can   O   O
be   O   O
found   O   O
in   O   O
.   O   O
The   O   O
resting   RestingStateImaging   O
state   RestingStateImaging   O
data   RestingStateImaging   O
were   O   O
acquired   O   O
transverse   O   O
to   O   O
the   O   O
AC-PC   O   O
plane   O   O
,   O   O
with   O   O
a   T2WeightedImaging   O
T2   T2WeightedImaging   T1WeightedImaging
*   T2WeightedImaging   T1WeightedImaging
-   T2WeightedImaging   T1WeightedImaging
weighted   T2WeightedImaging   T1WeightedImaging
single   O   O
shot   O   MolecularImaging
echo   O   MolecularImaging
planar   O   MolecularImaging
imaging   O   MolecularImaging
(   O   MolecularImaging
EPI   O   MolecularImaging
)   O   MolecularImaging
pulse   O   O
sequence   O   O
designed   O   O
to   O   O
measure   O   O
whole   O   O
brain   O   O
BOLD   O   O
contrast   O   O
with   O   O
optimal   O   O
temporal   O   O
and   O   O
spatial   O   O
resolution   O   O
[   O   O
repetition   O   O
time   O   O
(   O   O
TR   O   O
)   O   O
=   O   O
2000ms   O   O
;   O   O
echo   O   O
time   O   O
(   O   O
TE   O   O
)   O   O
=   O   O
30ms   O   O
;   O   O
Flip   O   O
angle   O   O
(   O   O
FA   O   O
)   O   O
=   O   O
90   O   O
degrees   O   O
;   O   O
field   O   O
of   O   O
view   O   O
(   O   O
FOV   O   O
)   O   O
=   O   O
240   O   O
mm   O   O
;   O   O
Slice   O   O
thickness   O   O
=   O   O
2.5   O   O
mm   O   O
;   O   O
Slice   O   O
skip   O   O
0.5   O   O
;   O   O
Slice   O   O
location   O   O
=   O   O
Pat   O   O
.   O   O
Spec   O   O
;   O   O
Fat   O   O
saturation   O   O
=   O   O
SPIR   O   O
;   O   O
Reps   O   O
=   O   O
240   O   O
;   O   O
NEX   O   O
=   O   O
1   O   O
;   O   O
yielding   O   O
36   O   O
contiguous   O   O
transverse   O   O
functional   O   O
images   O   O
in   O   O
an   O   O
80   O   O
×   O   O
80   O   O
matrix   O   O
with   O   O
an   O   O
isotropic   O   O
resolution   O   O
of   O   O
3.0   O   O
mm3   O   O
]   O   O
.   O   O
T1   T1WeightedImaging   Reference
-   T1WeightedImaging   Reference
weighted   T1WeightedImaging   Reference
anatomic   O   Reference
reference   O   Reference
images   O   Reference
were   O   O
acquired   O   O
in   O   O
the   O   O
same   O   O
planes   O   O
and   O   O
thickness   O   O
immediately   O   O
following   O   O
the   O   O
resting   O   O
scans   O   O
.   O   O
fMRI   FunctionalMagneticResonanceImaging   O
data   FunctionalMagneticResonanceImaging   O
analysis   FunctionalMagneticResonanceImaging   O
Resting   RestingStateImaging   O
state   RestingStateImaging   O
data   RestingStateImaging   O
were   O   O
analyzed   O   O
using   O   O
a   O   O
seed   O   O
driven   O   O
approach   O   O
(   O   O
http   O   O
:   O   O
/   O   O
/   O   O
www.nitrc.org   O   O
/   O   O
projects   O   O
/   O   O
conn   O   O
)   O   O
.   O   O
We   O   O
used   O   O
methods   O   O
that   O   O
minimize   O   O
the   O   O
influence   O   O
of   O   O
motion   O   O
and   O   O
artifact   O   O
and   O   O
that   O   O
allow   O   O
for   O   O
valid   O   O
identification   O   O
of   O   O
correlated   O   O
and   O   O
anticorrelated   O   O
networks   O   O
.   O   O
Data   O   O
were   O   O
slice   O   O
time   O   O
corrected   O   O
,   O   O
realigned   O   O
,   O   O
coregistered   O   O
,   O   O
normalized   O   O
,   O   O
and   O   O
spatially   O   O
smoothed   O   O
with   O   O
a   O   O
6   O   O
-   O   O
mm   O   O
kernel   O   O
.   O   O
To   O   O
address   O   O
the   O   O
spurious   O   O
correlations   O   O
in   O   O
resting-state   O   O
networks   O   O
caused   O   O
by   O   O
head   O   O
motion   O   O
we   O   O
used   O   O
quality   O   O
assurance   O   O
software   O   O
Artifact   O   O
Detection   O   O
Tools   O   O
(   O   O
http   O   O
:   O   O
/   O   O
/   O   O
www.nitrc.org   O   O
/   O   O
projects   O   O
/   O   O
artifact_detect   O   O
;   O   O
http   O   O
:   O   O
/   O   O
/   O   O
www.nitrc.org   O   O
/   O   O
projects   O   O
/   O   O
conn   O   O
)   O   O
to   O   O
identify   O   O
problematic   O   O
time   O   O
points   O   O
during   O   O
the   O   O
scan   O   O
.   O   O
Specifically   O   O
,   O   O
an   O   O
image   O   O
was   O   O
defined   O   O
as   O   O
an   O   O
outlier   O   O
if   O   O
the   O   O
head   O   O
displacement   O   O
in   O   O
x   O   O
,   O   O
y   O   O
,   O   O
or   O   O
z   O   O
direction   O   O
was   O   O
greater   O   O
than   O   O
.5mm   O   O
from   O   O
the   O   O
previous   O   O
frame   O   O
,   O   O
or   O   O
if   O   O
the   O   O
global   O   O
mean   O   O
intensity   O   O
in   O   O
the   O   O
image   O   O
was   O   O
greater   O   O
than   O   O
3   O   O
standard   O   O
deviations   O   O
from   O   O
the   O   O
mean   O   O
image   O   O
intensity   O   O
for   O   O
the   O   O
entire   O   O
resting   O   O
scan   O   O
.   O   O
A   O   O
single   O   O
regressor   O   O
for   O   O
each   O   O
outlier   O   O
image   O   O
was   O   O
included   O   O
in   O   O
the   O   O
first   O   O
level   O   O
general   O   O
linear   O   O
model   O   O
along   O   O
with   O   O
motion   O   O
parameters   O   O
and   O   O
first   O   O
order   O   O
derivatives   O   O
.   O   O
Physiological   O   O
and   O   O
other   O   O
spurious   O   O
sources   O   O
of   O   O
noise   O   O
were   O   O
estimated   O   O
and   O   O
regressed   O   O
using   O   O
the   O   O
anatomical   O   O
CompCor   O   O
method   O   O
(   O   O
aCompCor   O   O
)   O   O
as   O   O
opposed   O   O
to   O   O
global   O   O
signal   O   O
regression   O   O
,   O   O
a   O   O
widely   O   O
used   O   O
preprocessing   O   O
method   O   O
known   O   O
to   O   O
artificially   O   O
introduce   O   O
negative   O   O
correlations   O   O
.   O   O
The   O   O
anatomical   StructuralImaging   O
image   StructuralImaging   O
for   O   O
each   O   O
participant   O   O
was   O   O
segmented   O   O
into   O   O
white   O   O
matter   O   O
,   O   O
grey   O   O
matter   O   O
,   O   O
and   O   O
cerebrospinal   O   O
fluid   O   O
(   O   O
CSF   O   O
)   O   O
masks   O   O
using   O   O
SPM8   O   O
.   O   O
To   O   O
minimize   O   O
partial   O   O
voluming   O   O
with   O   O
grey   O   O
matter   O   O
,   O   O
the   O   O
white   O   O
matter   O   O
and   O   O
CSF   O   O
masks   O   O
were   O   O
eroded   O   O
by   O   O
one   O   O
voxel   O   O
,   O   O
which   O   O
resulted   O   O
in   O   O
substantially   O   O
smaller   O   O
masks   O   O
than   O   O
the   O   O
original   O   O
segmentations   O   O
.   O   O
The   O   O
eroded   O   O
white   O   O
matter   O   O
and   O   O
CSF   O   O
masks   O   O
were   O   O
then   O   O
used   O   O
as   O   O
noise   O   O
regions   O   O
of   O   O
interest   O   O
(   O   O
ROI   O   O
)   O   O
.   O   O
Signals   O   O
from   O   O
the   O   O
white   O   O
matter   O   O
and   O   O
CSF   O   O
noise   O   O
ROIs   O   O
were   O   O
extracted   O   O
from   O   O
the   O   O
unsmoothed   O   O
functional   O   O
volumes   O   O
to   O   O
avoid   O   O
additional   O   O
risk   O   O
of   O   O
contaminating   O   O
white   O   O
matter   O   O
and   O   O
CSF   O   O
signals   O   O
with   O   O
grey   O   O
matter   O   O
signals   O   O
.   O   O
Previous   O   O
results   O   O
showed   O   O
that   O   O
aCompCor   O   O
signals   O   O
were   O   O
considerably   O   O
different   O   O
from   O   O
the   O   O
global   O   O
signal   O   O
,   O   O
as   O   O
regressing   O   O
higher   O   O
order   O   O
principal   O   O
components   O   O
of   O   O
the   O   O
global   O   O
signal   O   O
diminished   O   O
both   O   O
positive   O   O
and   O   O
negative   O   O
correlations   O   O
whereas   O   O
regressing   O   O
aCompCor   O   O
signals   O   O
resulted   O   O
in   O   O
stronger   O   O
anticorrelations   O   O
and   O   O
eliminated   O   O
spurious   O   O
correlations   O   O
.   O   O
Based   O   O
on   O   O
previous   O   O
results   O   O
,   O   O
five   O   O
principal   O   O
components   O   O
of   O   O
the   O   O
signals   O   O
from   O   O
white   O   O
matter   O   O
and   O   O
CSF   O   O
noise   O   O
ROIs   O   O
were   O   O
removed   O   O
with   O   O
regression   O   O
.   O   O
A   O   O
temporal   O   O
band-pass   O   O
filter   O   O
of   O   O
0.009   O   O
Hz   O   O
to   O   O
0.08   O   O
Hz   O   O
was   O   O
applied   O   O
to   O   O
the   O   O
time   O   O
series   O   O
.   O   O
The   O   O
residual   O   O
BOLD   O   O
time-series   O   O
was   O   O
band-pass   O   O
filtered   O   O
over   O   O
a   O   O
low-frequency   O   O
window   O   O
of   O   O
interest   O   O
(   O   O
0.009Hz   O   O
<   O   O
f   O   O
<   O   O
0.08Hz   O   O
)   O   O
.   O   O
Correlation   O   O
maps   O   O
were   O   O
produced   O   O
by   O   O
extracting   O   O
the   O   O
residual   O   O
BOLD   O   O
time   O   O
course   O   O
from   O   O
seed   O   O
regions   O   O
based   O   O
on   O   O
the   O   O
literature   O   O
.   O   O
The   O   O
DMN   O   O
seed   O   O
was   O   O
defined   O   O
using   O   O
a   O   O
10   O   O
mm   O   O
sphere   O   O
around   O   O
peak   O   O
MPFC   O   O
coordinates   O   O
,   O   O
as   O   O
specified   O   O
in   O   O
.   O   O
Pearson   O   O
’   O   O
s   O   O
correlation   O   O
coefficients   O   O
were   O   O
then   O   O
calculated   O   O
between   O   O
the   O   O
DMN   O   O
time   O   O
course   O   O
and   O   O
the   O   O
time   O   O
course   O   O
of   O   O
all   O   O
other   O   O
voxels   O   O
in   O   O
the   O   O
brain   O   O
.   O   O
Correlation   O   O
coefficients   O   O
were   O   O
converted   O   O
to   O   O
normally   O   O
distributed   O   O
scores   O   O
using   O   O
Fisher   O   O
’   O   O
s   O   O
transformation   O   O
to   O   O
allow   O   O
for   O   O
second-level   O   O
General   O   O
Linear   O   O
Model   O   O
analyses   O   O
.   O   O
Second-level   O   O
within-group   O   O
(   O   O
one   O   O
sample   O   O
t-tests   O   O
)   O   O
and   O   O
between   O   O
group   O   O
(   O   O
ANOVA   O   O
)   O   O
analyses   O   O
were   O   O
performed   O   O
on   O   O
the   O   O
Z-maps   O   O
from   O   O
the   O   O
MPFC   O   O
.   O   O
Correction   O   O
for   O   O
multiple   O   O
comparisons   O   O
on   O   O
analyses   O   O
were   O   O
implemented   O   O
with   O   O
an   O   O
FDR   O   O
correction   O   O
of   O   O
p   O   O
<   O   O
0.001   O   O
.   O   O
Reduced   O   O
Parietal   O   O
Alpha   O   O
Power   O   O
and   O   O
Psychotic   O   O
Symptoms   O   O
:   O   O
Test-Retest   O   O
Reliability   O   O
of   O   O
Resting-State   O   RestingStateImaging
Magnetoencephalography   O   O
in   O   O
Schizophrenia   O   Schizophrenia
and   O   O
Healthy   O   O
Controls   O   O
Background   O   O
:   O   O
Despite   O   O
increased   O   O
reporting   O   O
of   O   O
resting-state   O   RestingStateImaging
magnetoencephalography   O   O
(   O   O
MEG   O   O
)   O   O
,   O   O
reliability   O   O
of   O   O
those   O   O
measures   O   O
remains   O   O
scarce   O   O
and   O   O
predominately   O   O
reported   O   O
in   O   O
healthy   NoKnownDisorder   ControlSubject
controls   NoKnownDisorder   ControlSubject
(   O   O
HC   O   O
)   O   O
.   O   O
As   O   O
such   O   O
,   O   O
there   O   O
is   O   O
limited   O   O
knowledge   O   O
on   O   O
MEG   O   O
resting-state   O   O
reliability   O   O
in   O   O
schizophrenia   Schizophrenia   O
(   O   O
SZ   O   O
)   O   O
.   O   O
Methods   O   O
:   O   O
To   O   O
address   O   O
test-retest   O   O
reliability   O   O
in   O   O
psychosis   O   O
,   O   O
a   O   O
reproducibility   O   O
study   O   O
of   O   O
26   O   O
participants   O   O
(   O   O
13   O   O
-   O   O
SZ   O   O
,   O   O
13   O   O
-   O   O
HC   O   O
)   O   O
was   O   O
performed   O   O
.   O   O
We   O   O
collected   O   O
eyes   O   O
open   O   O
and   O   O
eyes   O   O
closed   O   O
resting-state   RestingStateImaging   O
data   RestingStateImaging   O
during   O   O
4   O   O
separate   O   O
instances   O   O
(   O   O
2   O   O
Visits   O   O
,   O   O
2   O   O
runs   O   O
per   O   O
visit   O   O
)   O   O
to   O   O
estimate   O   O
spectral   O   O
power   O   O
reliability   O   O
(   O   O
power   O   O
,   O   O
normalized   O   O
power   O   O
,   O   O
alpha   O   O
reactivity   O   O
)   O   O
across   O   O
one   O   O
hour   O   O
and   O   O
one   O   O
week   O   O
.   O   O
Intraclass   O   O
correlation   O   O
coefficients   O   O
(   O   O
ICCs   O   O
)   O   O
were   O   O
calculated   O   O
.   O   O
For   O   O
source   O   O
modeling   O   O
,   O   O
we   O   O
applied   O   O
an   O   O
anatomically   O   O
constrained   O   O
linear   O   O
estimation   O   O
inverse   O   O
model   O   O
known   O   O
as   O   O
dynamic   O   O
statistical   O   O
parametric   O   O
mapping   O   O
(   O   O
MNE   O   O
dSPM   O   O
)   O   O
and   O   O
source-based   O   O
connectivity   O   O
using   O   O
the   O   O
weighted   O   O
phase   O   O
lag   O   O
index   O   O
.   O   O
Results   O   O
:   O   O
Across   O   O
one   O   O
week   O   O
there   O   O
was   O   O
excellent   O   O
test-retest   O   O
reliability   O   O
in   O   O
global   O   O
spectral   O   O
measures   O   O
in   O   O
theta-gamma   O   O
bands   O   O
(   O   O
HC   O   O
ICCAvg   O   O
=   O   O
0.87   O   O
,   O   O
SZ   O   O
ICCAvg   O   O
=   O   O
0.87   O   O
)   O   O
,   O   O
regional   O   O
spectral   O   O
measures   O   O
in   O   O
all   O   O
bands   O   O
(   O   O
HC   O   O
ICCAvg   O   O
=   O   O
0.86   O   O
,   O   O
SZ   O   O
ICCAvg   O   O
=   O   O
0.80   O   O
)   O   O
,   O   O
and   O   O
parietal   O   O
alpha   O   O
measures   O   O
(   O   O
HC   O   O
ICCAvg   O   O
=   O   O
0.90   O   O
,   O   O
SZ   O   O
ICCAvg   O   O
=   O   O
0.84   O   O
)   O   O
.   O   O
Conversely   O   O
,   O   O
functional   O   O
connectivity   O   O
had   O   O
poor   O   O
reliability   O   O
,   O   O
as   O   O
did   O   O
source   O   O
spectral   O   O
power   O   O
across   O   O
one   O   O
hour   O   O
for   O   O
SZ   Schizophrenia   O
.   O   O
Relative   O   O
to   O   O
HC   NoKnownDisorder   O
,   O   O
SZ   Schizophrenia   O
also   O   O
had   O   O
reduced   O   O
parietal   O   O
alpha   O   O
normalized   O   O
power   O   O
during   O   O
eyes   O   O
closed   O   O
only   O   O
,   O   O
reduced   O   O
alpha   O   O
reactivity   O   O
,   O   O
and   O   O
an   O   O
association   O   O
between   O   O
higher   O   O
PANSS   O   O
positive   O   O
scores   O   O
and   O   O
lower   O   O
parietal   O   O
alpha   O   O
power   O   O
.   O   O
Conclusions   O   O
:   O   O
There   O   O
was   O   O
excellent   O   O
to   O   O
good   O   O
test-retest   O   O
reliability   O   O
in   O   O
most   O   O
MEG   Magnetoencephalography   O
spectral   O   O
measures   O   O
with   O   O
a   O   O
few   O   O
exceptions   O   O
in   O   O
the   O   O
schizophrenia   Schizophrenia   O
patient   O   O
group   O   O
.   O   O
Overall   O   O
,   O   O
these   O   O
findings   O   O
encourage   O   O
the   O   O
use   O   O
of   O   O
resting-state   O   O
MEG   O   O
while   O   O
emphasizing   O   O
the   O   O
importance   O   O
of   O   O
determining   O   O
reliability   O   O
in   O   O
clinical   O   O
populations   O   O
.   O   O
Materials   StudyMethod   StudyMethod
and   StudyMethod   StudyMethod
Methods   StudyMethod   StudyMethod
Participants   O   O
The   O   O
current   O   O
study   O   O
included   O   O
13   O   O
individuals   O   O
diagnosed   O   Schizophrenia
with   O   Schizophrenia
schizophrenia   Schizophrenia   Schizophrenia
(   Schizophrenia   Schizophrenia
SZ   Schizophrenia   Schizophrenia
)   Schizophrenia   Schizophrenia
and   O   O
13   O   O
healthy   NoKnownDisorder   ControlSubject
controls   NoKnownDisorder   ControlSubject
(   NoKnownDisorder   ControlSubject
HC   NoKnownDisorder   ControlSubject
)   NoKnownDisorder   ControlSubject
,   O   O
age   O   O
and   O   O
gender   O   O
matched   O   O
,   O   O
Table   O   O
1   O   O
.   O   O
Informed   O   O
consent   O   O
was   O   O
obtained   O   O
from   O   O
all   O   O
participants   O   O
according   O   O
to   O   O
institutional   O   O
guidelines   O   O
.   O   O
The   O   O
study   O   O
was   O   O
approved   O   O
by   O   O
the   O   O
University   O   O
of   O   O
New   O   O
Mexico   O   O
Health   O   O
Sciences   O   O
Center   O   O
Human   O   O
Research   O   O
Review   O   O
Committee   O   O
.   O   O
All   O   O
participants   O   O
were   O   O
within   O   O
21   O   O
–   O   O
49   O   O
years   O   O
of   O   O
age   O   O
with   O   O
no   O   O
history   O   O
of   O   O
neurological   O   O
disorder   O   O
(   O   O
e.g   O   O
.   O   O
epilepsy   O   O
)   O   O
,   O   O
no   O   O
history   O   O
of   O   O
major   O   O
head   O   O
trauma   O   O
(   O   O
loss   O   O
of   O   O
consciousness   O   O
>   O   O
5   O   O
min   O   O
)   O   O
,   O   O
no   O   O
current   O   O
substance   O   O
abuse   O   O
diagnosis   O   O
(   O   O
excluding   O   O
nicotine   O   O
)   O   O
,   O   O
no   O   O
current   O   O
dependence   O   O
/   O   O
abuse   O   O
of   O   O
PCP   O   O
/   O   O
amphetamine   O   O
/   O   O
cocaine   O   O
within   O   O
the   O   O
past   O   O
12   O   O
months   O   O
,   O   O
and   O   O
were   O   O
not   O   O
currently   O   O
on   O   O
mood   O   O
stabilizers   O   O
such   O   O
as   O   O
lithium   O   O
or   O   O
valproic   O   O
acid   O   O
.   O   O
HC   NoKnownDisorder   O
had   O   O
IQ   O   O
scores   O   O
within   O   O
the   O   O
normal   O   O
range   O   O
and   O   O
no   O   O
history   O   O
of   O   O
developmental   O   O
delays   O   O
or   O   O
neurological   O   O
or   O   O
psychiatric   O   O
disorders   O   O
based   O   O
on   O   O
the   O   O
Structured   MentalHealthDiagnosisScale   O
Clinical   MentalHealthDiagnosisScale   O
Interview   MentalHealthDiagnosisScale   O
for   MentalHealthDiagnosisScale   O
DSM-IV-Non-patient   MentalHealthDiagnosisScale   O
(   MentalHealthDiagnosisScale   ThyroidNodule
SCIDNP   MentalHealthDiagnosisScale   ThyroidNodule
)   MentalHealthDiagnosisScale   ThyroidNodule
.   O   O
HCs   O   O
also   O   O
did   O   O
not   O   O
have   O   O
a   O   O
family   O   O
history   O   O
of   O   O
a   O   O
psychotic   O   O
disorder   O   O
in   O   O
first-degree   O   O
relatives   O   O
or   O   O
a   O   O
history   O   O
of   O   O
more   O   O
than   O   O
1   O   O
lifetime   O   O
depressive   O   O
episode   O   O
.   O   O
Participants   Schizophrenia   O
with   Schizophrenia   Schizophrenia
schizophrenia   Schizophrenia   Schizophrenia
were   O   O
confirmed   O   O
to   O   O
have   O   O
a   O   O
DSM-IV-TR   O   O
diagnosis   O   Schizophrenia
of   O   Schizophrenia
schizophrenia   Schizophrenia   Schizophrenia
with   O   O
the   O   O
Structured   MentalHealthDiagnosisScale   O
Clinical   MentalHealthDiagnosisScale   O
Interview   MentalHealthDiagnosisScale   O
for   MentalHealthDiagnosisScale   O
DSM-IV-Patient   MentalHealthDiagnosisScale   O
(   MentalHealthDiagnosisScale   SuicideIdeation
SCID-IP   MentalHealthDiagnosisScale   SuicideIdeation
)   MentalHealthDiagnosisScale   O
and   O   O
retrospective   O   O
clinical   O   O
stability   O   O
.   O   O
Participants   O   O
were   O   O
not   O   O
excluded   O   O
for   O   O
nicotine   O   O
use   O   O
,   O   O
however   O   O
,   O   O
they   O   O
were   O   O
not   O   O
allowed   O   O
to   O   O
smoke   O   O
within   O   O
1   O   O
hour   O   O
of   O   O
the   O   O
MEG   O   O
session   O   O
or   O   O
be   O   O
more   O   O
than   O   O
5   O   O
hours   O   O
from   O   O
their   O   O
previous   O   O
cigarette   O   O
to   O   O
avoid   O   O
confounds   O   O
of   O   O
acute   O   O
nicotine   O   O
exposure   O   O
or   O   O
withdrawal   O   O
.   O   O
The   O   O
following   O   O
assessments   O   O
were   O   O
collected   O   O
in   O   O
SZ   Schizophrenia   O
participants   O   O
and   O   O
reported   O   O
in   O   O
Table   O   O
1   O   O
:   O   O
Wechsler   NeurocognitiveTest   NationalAdultReadingTest
Test   NeurocognitiveTest   NationalAdultReadingTest
of   NeurocognitiveTest   NationalAdultReadingTest
Adult   NeurocognitiveTest   NationalAdultReadingTest
Reading   NeurocognitiveTest   NationalAdultReadingTest
(   NeurocognitiveTest   NationalAdultReadingTest
WTAR   NeurocognitiveTest   NationalAdultReadingTest
)   NeurocognitiveTest   NationalAdultReadingTest
,   NeurocognitiveTest   O
Standard   NeurocognitiveTest   StandardDeviationMeasure
and   NeurocognitiveTest   StandardDeviationMeasure
Predicted   NeurocognitiveTest   StandardDeviationMeasure
(   NeurocognitiveTest   O
premorbid   NeurocognitiveTest   O
)   NeurocognitiveTest   O
IQ   NeurocognitiveTest   Thing
,   O   O
Positive   PositiveandNegativeSyndromeScale   PositiveandNegativeSyndromeScale
and   PositiveandNegativeSyndromeScale   PositiveandNegativeSyndromeScale
Negative   PositiveandNegativeSyndromeScale   PositiveandNegativeSyndromeScale
Syndrome   PositiveandNegativeSyndromeScale   PositiveandNegativeSyndromeScale
Scale   PositiveandNegativeSyndromeScale   PositiveandNegativeSyndromeScale
(   PositiveandNegativeSyndromeScale   PositiveandNegativeSyndromeScale
PANSS   PositiveandNegativeSyndromeScale   PositiveandNegativeSyndromeScale
)   PositiveandNegativeSyndromeScale   PositiveandNegativeSyndromeScale
,   O   O
antipsychotic   O   O
medication   O   O
dose   O   O
information   O   O
,   O   O
and   O   O
duration   O   O
of   O   O
illness   O   O
.   O   O
PANSS   PositiveandNegativeSyndromeScale   O
scores   O   O
were   O   O
determined   O   O
for   O   O
each   O   O
visit   O   O
.   O   O
Antipsychotic   O   O
medication   O   O
was   O   O
converted   O   O
to   O   O
olanzapine   O   O
equivalents   O   O
for   O   O
comparison   O   O
between   O   O
medication   O   O
.   O   O
Duration   O   O
of   O   O
illness   O   O
was   O   O
calculated   O   O
by   O   O
subtracting   O   O
age   O   O
at   O   O
onset   O   O
of   O   O
psychotic   O   O
symptoms   O   O
from   O   O
current   O   O
age   O   O
.   O   O
MEG   O   Acromegaly
Behavioral   O   O
Tasks   O   O
All   O   O
participants   O   O
had   O   O
two   O   O
visits   O   O
across   O   O
7   O   O
days   O   O
[   O   O
HC   O   O
=   O   O
7.54   O   O
days   O   O
±   O   O
60   O   O
minutes   O   O
,   O   O
SZ   O   O
=   O   O
7.84   O   O
days   O   O
±   O   O
51   O   O
minutes   O   O
]   O   O
.   O   O
Time   O   O
of   O   O
day   O   O
between   O   O
visits   O   O
was   O   O
matched   O   O
to   O   O
take   O   O
into   O   O
account   O   O
circadian   O   O
rhythm   O   O
.   O   O
Each   O   O
visit   O   O
began   O   O
with   O   O
a   O   O
10   O   O
-   O   O
minute   O   O
rest   RestingStateImaging   O
task   RestingStateImaging   O
(   O   O
referred   O   O
to   O   O
as   O   O
Rest10   O   O
)   O   O
and   O   O
ended   O   O
with   O   O
a   O   O
4   O   O
-   O   O
minute   O   O
rest   RestingStateImaging   O
task   RestingStateImaging   O
(   O   O
referred   O   O
to   O   O
as   O   O
Rest4   O   O
)   O   O
,   O   O
see   O   O
Figure   O   O
1   O   O
.   O   O
No   O   O
responses   O   O
were   O   O
required   O   O
from   O   O
the   O   O
participant   O   O
;   O   O
however   O   O
,   O   O
participants   O   O
were   O   O
instructed   O   O
to   O   O
attend   O   O
the   O   O
instructions   O   O
for   O   O
prompts   O   O
to   O   O
close   O   O
their   O   O
eyes   O   O
or   O   O
fixate   O   O
on   O   O
a   O   O
white   O   O
cross   O   O
.   O   O
Each   O   O
task   O   O
alternated   O   O
between   O   O
EC   O   O
and   O   O
EO   O   O
.   O   O
In   O   O
total   O   O
,   O   O
resting-state   RestingStateImaging   RestingStateImaging
activity   RestingStateImaging   O
was   O   O
recorded   O   O
4   O   O
separate   O   O
times   O   O
with   O   O
14   O   O
minutes   O   O
of   O   O
EO   O   O
and   O   O
14   O   O
minutes   O   O
of   O   O
EC   O   O
.   O   O
MEG   O   O
Data   O   O
Acquisition   O   O
MEG   Magnetoencephalography   O
data   O   O
were   O   O
collected   O   O
in   O   O
a   O   O
magnetically   O   O
shielded   O   O
room   O   O
(   O   O
Vacuumschmelze   O   O
–   O   O
Ak3B   O   O
)   O   O
at   O   O
the   O   O
Mind   O   O
Research   O   O
Network   O   O
in   O   O
Albuquerque   O   O
,   O   O
New   O   O
Mexico   O   O
using   O   O
a   O   O
306   O   O
-   O   O
channel   O   O
whole-head   O   O
MEG   Magnetoencephalography   O
system   O   O
(   O   O
Elekta   O   O
Neuromag   O   O
)   O   O
with   O   O
a   O   O
sampling   O   O
rate   O   O
of   O   O
1000   O   O
Hz   O   O
and   O   O
an   O   O
antialiasing   O   O
filter   O   O
with   O   O
a   O   O
passband   O   O
of   O   O
0.1   O   O
–   O   O
330   O   O
Hz   O   O
.   O   O
Prior   O   O
to   O   O
data   O   O
acquisition   O   O
,   O   O
four   O   O
electromagnetic   O   O
coils   O   O
were   O   O
placed   O   O
on   O   O
the   O   O
participant   O   O
’   O   O
s   O   O
mastoid   O   O
bone   O   O
and   O   O
upper   O   O
forehead   O   O
,   O   O
along   O   O
with   O   O
electro-oculogram   O   O
and   O   O
electrocardiogram   O   O
channels   O   O
.   O   O
The   O   O
location   O   O
of   O   O
the   O   O
coils   O   O
were   O   O
registered   O   O
to   O   O
the   O   O
nasion   O   O
and   O   O
preauricular   O   O
points   O   O
using   O   O
three-dimensional   O   O
digitization   O   O
equipment   O   O
(   O   O
Polhemus   O   O
FastTrack   O   O
)   O   O
.   O   O
Participants   O   O
sat   O   O
upright   O   O
in   O   O
the   O   O
MEG   Magnetoencephalography   O
during   O   O
the   O   O
task   O   O
.   O   O
Continuous   O   O
Head   O   O
Position   O   O
Indicator   O   O
(   O   O
cHPI   O   O
)   O   O
monitoring   O   O
allowed   O   O
for   O   O
motion   O   O
correction   O   O
.   O   O
Head   O   O
position   O   O
was   O   O
checked   O   O
between   O   O
visits   O   O
.   O   O
For   O   O
the   O   O
Rest10   RestingStateImaging   O
task   RestingStateImaging   O
,   O   O
average   O   O
Euclidean   O   O
distance   O   O
between   O   O
visits   O   O
was   O   O
4.62   O   O
mm   O   O
for   O   O
HC   NoKnownDisorder   O
and   O   O
6.06   O   O
mm   O   O
for   O   O
SZ   Schizophrenia   O
.   O   O
For   O   O
the   O   O
Rest4   RestingStateImaging   O
task   RestingStateImaging   O
,   O   O
the   O   O
distance   O   O
was   O   O
4.90   O   O
mm   O   O
for   O   O
HC   NoKnownDisorder   O
and   O   O
6.12   O   O
mm   O   O
for   O   O
SZ   Schizophrenia   O
.   O   O
Head   O   O
position   O   O
consistency   O   O
was   O   O
similar   O   O
between   O   O
HC   NoKnownDisorder   O
and   O   O
SZ   Schizophrenia   O
(   O   O
all   O   O
p   O   O
’   O   O
s   O   O
>   O   O
0.31   O   O
)   O   O
.   O   O
Structural   O   StructuralImaging
MRI   O   StructuralImaging
Data   O   O
Acquisition   O   O
Structural   StructuralImaging   O
MRIs   StructuralImaging   O
were   O   O
obtained   O   O
for   O   O
mapping   O   O
source   O   O
locations   O   O
.   O   O
Sagittal   O   T1WeightedImaging
T1   T1WeightedImaging   T1WeightedImaging
-   T1WeightedImaging   T1WeightedImaging
weighted   T1WeightedImaging   T1WeightedImaging
anatomical   StructuralImaging   T1WeightedImaging
MR   StructuralImaging   T1WeightedImaging
images   StructuralImaging   O
were   O   O
obtained   O   O
using   O   O
a   O   O
Siemens   O   O
TIM   O   O
Trio   O   O
3   O   O
Tesla   O   O
MRI   O   O
system   O   O
with   O   O
a   O   O
32   O   O
-   O   O
channel   O   O
head   O   O
coil   O   O
.   O   O
Parameters   O   O
of   O   O
the   O   O
multiecho   O   O
3D   O   O
MPRAGE   T1WeightedImaging   O
sequence   T1WeightedImaging   O
were   O   O
:   O   O
TR   O   O
/   O   O
TE   O   O
/   O   O
TI   O   O
=   O   O
2530   O   O
/   O   O
1.64   O   O
,   O   O
3.5   O   O
,   O   O
5.36   O   O
,   O   O
7.22   O   O
,   O   O
9.08   O   O
/   O   O
1200   O   O
ms   O   O
,   O   O
flip   O   O
angle   O   O
=   O   O
7   O   O
°   O   O
,   O   O
field   O   O
of   O   O
view   O   O
(   O   O
FOV   O   O
)   O   O
=   O   O
256   O   O
mm   O   O
x   O   O
256   O   O
mm   O   O
,   O   O
matrix   O   O
=   O   O
256   O   O
×   O   O
256   O   O
,   O   O
1   O   O
mm   O   O
thick   O   O
slice   O   O
,   O   O
192   O   O
slices   O   O
,   O   O
GRAPPA   O   O
acceleration   O   O
=   O   O
2   O   O
.   O   O
MEG   O   O
Data   O   O
Preprocessing   O   O
Raw   O   O
MEG   Magnetoencephalography   O
data   O   O
were   O   O
filtered   O   O
for   O   O
noise   O   O
and   O   O
corrected   O   O
for   O   O
head   O   O
motion   O   O
with   O   O
the   O   O
Neuromag   O   O
Max-Filter   O   O
2.2   O   O
software   O   O
using   O   O
the   O   O
temporal   O   O
extension   O   O
of   O   O
signal   O   O
space   O   O
separation   O   O
(   O   O
t-SSS   O   O
)   O   O
method   O   O
with   O   O
movement   O   O
compensation   O   O
.   O   O
MEG   Magnetoencephalography   O
data   O   O
from   O   O
each   O   O
subject   O   O
’   O   O
s   O   O
Visit   O   O
2   O   O
was   O   O
transformed   O   O
to   O   O
Visit   O   O
1   O   O
head   O   O
position   O   O
using   O   O
Maxfilter   O   O
2.2   O   O
MaxMove   O   O
option   O   O
to   O   O
ensure   O   O
equivalent   O   O
sensor   O   O
locations   O   O
between   O   O
visits   O   O
.   O   O
No   O   O
downsampling   O   O
of   O   O
the   O   O
data   O   O
was   O   O
implemented   O   O
at   O   O
the   O   O
preprocessing   O   O
stage   O   O
.   O   O
Heartbeat   O   O
and   O   O
eye-blink   O   O
artifacts   O   O
were   O   O
automatically   O   O
detected   O   O
and   O   O
removed   O   O
using   O   O
signal   O   O
space   O   O
projection   O   O
(   O   O
SSP   O   O
)   O   O
in   O   O
MNE   O   O
software   O   O
.   O   O
The   O   O
continuous   O   O
data   O   O
were   O   O
segmented   O   O
into   O   O
artifact-free   O   O
2   O   O
second   O   O
epochs   O   O
.   O   O
Epochs   O   O
in   O   O
which   O   O
the   O   O
magnetic   O   O
field   O   O
exceeded   O   O
5   O   O
pT   O   O
were   O   O
rejected   O   O
.   O   O
HC   NoKnownDisorder   O
had   O   O
2.4%   O   O
and   O   O
SZ   Schizophrenia   O
had   O   O
4.6%   O   O
of   O   O
all   O   O
epochs   O   O
rejected   O   O
.   O   O
The   O   O
total   O   O
number   O   O
of   O   O
epochs   O   O
used   O   O
for   O   O
further   O   O
analysis   O   O
included   O   O
401   O   O
EC   O   O
,   O   O
402   O   O
EO   O   O
epochs   O   O
in   O   O
HC   NoKnownDisorder   O
,   O   O
and   O   O
393   O   O
EC   O   O
,   O   O
403   O   O
EO   O   O
epochs   O   O
in   O   O
SZ   Schizophrenia   O
.   O   O
The   O   O
number   O   O
of   O   O
closed   O   O
/   O   O
open   O   O
epochs   O   O
did   O   O
not   O   O
differ   O   O
between   O   O
groups   O   O
(   O   O
all   O   O
p   O   O
’   O   O
s   O   O
>   O   O
0.25   O   O
)   O   O
.   O   O
MEG   O   O
Spectral   O   O
Analyses   O   O
For   O   O
sensor   O   O
analysis   O   O
,   O   O
we   O   O
applied   O   O
the   O   O
summary   O   O
spectral   O   O
measures   O   O
described   O   O
in   O   O
to   O   O
simplify   O   O
multi-channel   O   O
MEG   Magnetoencephalography   O
spectral   O   O
data   O   O
.   O   O
Using   O   O
only   O   O
planar   O   O
gradiometers   O   O
,   O   O
the   O   O
sensor   O   O
array   O   O
was   O   O
divided   O   O
into   O   O
left   O   O
and   O   O
right   O   O
equivalent   O   O
regions   O   O
,   O   O
see   O   O
Figure   O   O
2   O   O
.   O   O
Spectral   O   O
power   O   O
was   O   O
estimated   O   O
using   O   O
Matlab   O   O
’   O   O
s   O   O
FFT   O   O
function   O   O
with   O   O
a   O   O
window   O   O
size   O   O
of   O   O
2048   O   O
for   O   O
the   O   O
following   O   O
frequency   O   O
bands   O   O
:   O   O
Delta   O   O
(   O   O
1   O   O
–   O   O
4   O   O
Hz   O   O
)   O   O
,   O   O
Theta   O   O
(   O   O
5   O   O
–   O   O
8   O   O
Hz   O   O
)   O   O
,   O   O
Alpha   O   O
(   O   O
9   O   O
–   O   O
13   O   O
Hz   O   O
)   O   O
,   O   O
Beta   O   O
(   O   O
14   O   O
–   O   O
29   O   O
Hz   O   O
)   O   O
,   O   O
and   O   O
Gamma   O   O
(   O   O
31   O   O
–   O   O
58   O   O
Hz   O   O
)   O   O
.   O   O
Spectral   O   O
measures   O   O
included   O   O
:   O   O
power   O   O
,   O   O
normalized   O   O
power   O   O
,   O   O
half-power   O   O
,   O   O
Shannon   O   O
Spectral   O   O
Entropy   O   O
(   O   O
SSE   O   O
)   O   O
,   O   O
and   O   O
alpha   O   O
reactivity   O   O
.   O   O
Normalized   O   O
power   O   O
was   O   O
obtained   O   O
by   O   O
dividing   O   O
the   O   O
power   O   O
within   O   O
the   O   O
frequency   O   O
band   O   O
by   O   O
total   O   O
1   O   O
–   O   O
50   O   O
Hz   O   O
power   O   O
.   O   O
Half   O   O
power   O   O
was   O   O
defined   O   O
as   O   O
the   O   O
midpoint   O   O
frequency   O   O
where   O   O
half   O   O
of   O   O
the   O   O
power   O   O
is   O   O
below   O   O
/   O   O
above   O   O
for   O   O
the   O   O
1   O   O
–   O   O
50   O   O
Hz   O   O
range   O   O
and   O   O
indicates   O   O
overall   O   O
spectral   O   O
power   O   O
shifts   O   O
from   O   O
low   O   O
to   O   O
high   O   O
frequencies   O   O
.   O   O
Alpha   O   O
reactivity   O   O
was   O   O
calculated   O   O
using   O   O
normalized   O   O
spectral   O   O
power   O   O
values   O   O
with   O   O
the   O   O
following   O   O
:   O   O
(   O   O
EC-EO   O   O
)   O   O
/   O   O
EO   O   O
.   O   O
Global   O   O
measures   O   O
were   O   O
the   O   O
average   O   O
of   O   O
all   O   O
regions   O   O
and   O   O
gradiometers   O   O
.   O   O
For   O   O
source   O   O
analysis   O   O
,   O   O
the   O   O
cortical   O   O
surface   O   O
of   O   O
each   O   O
participant   O   O
was   O   O
reconstructed   O   O
from   O   O
T1   T1WeightedImaging   T1WeightedImaging
-   T1WeightedImaging   T1WeightedImaging
weighted   T1WeightedImaging   T1WeightedImaging
MRI   O   T1WeightedImaging
files   O   T1WeightedImaging
using   O   O
FreeSurfer   O   O
with   O   O
a   O   O
repeatedly   O   O
subdivided   O   O
octahedron   O   O
as   O   O
the   O   O
spatial   O   O
subsampling   O   O
method   O   O
,   O   O
creating   O   O
4,098   O   O
locations   O   O
per   O   O
hemisphere   O   O
with   O   O
a   O   O
source   O   O
space   O   O
of   O   O
4.9   O   O
mm   O   O
.   O   O
Source   O   O
analysis   O   O
was   O   O
performed   O   O
with   O   O
MNE   O   O
software   O   O
using   O   O
an   O   O
anatomically   O   O
constrained   O   O
linear   O   O
estimation   O   O
inverse   O   O
model   O   O
known   O   O
as   O   O
dynamic   O   O
statistical   O   O
parametric   O   O
mapping   O   O
(   O   O
dSPM   O   O
)   O   O
.   O   O
The   O   O
regularization   O   O
parameter   O   O
corresponded   O   O
with   O   O
a   O   O
signal-to-noise   O   O
ratio   O   O
of   O   O
3   O   O
.   O   O
Source   O   O
orientation   O   O
had   O   O
a   O   O
loose   O   O
constraint   O   O
of   O   O
0.2   O   O
.   O   O
The   O   O
forward   O   O
solution   O   O
was   O   O
calculated   O   O
with   O   O
a   O   O
single   O   O
layer   O   O
(   O   O
inner   O   O
skull   O   O
)   O   O
boundary   O   O
element   O   O
method   O   O
.   O   O
The   O   O
dSPM   O   O
inverse   O   O
model   O   O
identified   O   O
where   O   O
the   O   O
estimated   O   O
current   O   O
at   O   O
each   O   O
cortical   O   O
surface   O   O
vertex   O   O
differed   O   O
significantly   O   O
from   O   O
baseline   O   O
noise   O   O
(   O   O
empty   O   O
room   O   O
data   O   O
)   O   O
.   O   O
Power   O   O
spectral   O   O
density   O   O
(   O   O
PSD   O   O
)   O   O
measures   O   O
were   O   O
computed   O   O
from   O   O
epochs   O   O
using   O   O
a   O   O
multi-taper   O   O
method   O   O
with   O   O
Discrete   O   O
Prolate   O   O
Spheroidal   O   O
Sequence   O   O
(   O   O
DPSS   O   O
)   O   O
windows   O   O
for   O   O
each   O   O
frequency   O   O
band   O   O
and   O   O
region   O   O
,   O   O
using   O   O
7   O   O
tapers   O   O
at   O   O
4   O   O
Hz   O   O
and   O   O
regions   O   O
of   O   O
interest   O   O
based   O   O
on   O   O
the   O   O
FreeSurfer   O   O
DKT   O   O
atlas   O   O
.   O   O
PSD   O   O
represents   O   O
the   O   O
average   O   O
spectral   O   O
power   O   O
derived   O   O
from   O   O
each   O   O
voxel   O   O
time   O   O
series   O   O
for   O   O
each   O   O
regional   O   O
label   O   O
.   O   O
Global   O   O
measures   O   O
were   O   O
data   O   O
from   O   O
all   O   O
regional   O   O
labels   O   O
averaged   O   O
.   O   O
Normalized   O   O
power   O   O
was   O   O
obtained   O   O
by   O   O
dividing   O   O
the   O   O
power   O   O
within   O   O
frequency   O   O
band   O   O
by   O   O
the   O   O
total   O   O
1   O   O
–   O   O
58   O   O
Hz   O   O
power   O   O
.   O   O
Functional   O   O
network   O   O
connectivity   O   O
was   O   O
estimated   O   O
using   O   O
a   O   O
debiased   O   O
estimator   O   O
of   O   O
the   O   O
squared   O   O
weighted   O   O
phase   O   O
lag   O   O
index   O   O
(   O   O
wPLI-debiased   O   O
)   O   O
.   O   O
The   O   O
FNC   O   O
measure   O   O
,   O   O
wPLI-debiased   O   O
,   O   O
detects   O   O
true   O   O
changes   O   O
in   O   O
phase-synchronization   O   O
,   O   O
while   O   O
reducing   O   O
the   O   O
influence   O   O
of   O   O
common   O   O
noise   O   O
sources   O   O
,   O   O
changes   O   O
in   O   O
phase   O   O
of   O   O
coherency   O   O
,   O   O
and   O   O
avoids   O   O
spuriously   O   O
increases   O   O
by   O   O
volume-conduction   O   O
.   O   O
It   O   O
estimates   O   O
the   O   O
extent   O   O
of   O   O
observed   O   O
phase   O   O
leads   O   O
and   O   O
lags   O   O
by   O   O
the   O   O
magnitude   O   O
of   O   O
the   O   O
imaginary   O   O
component   O   O
of   O   O
the   O   O
cross-spectrum   O   O
.   O   O
All   O   O
data   O   O
were   O   O
exported   O   O
to   O   O
MATLAB   O   O
(   O   O
2018a   O   O
,   O   O
MathWorks   O   O
)   O   O
and   O   O
run   O   O
through   O   O
custom   O   O
scripts   O   O
.   O   O
Intraclass   O   O
Correlation   O   O
(   O   O
ICC   O   O
)   O   O
ICC   O   O
estimates   O   O
and   O   O
their   O   O
95%   O   O
confidence   O   O
intervals   O   O
were   O   O
calculated   O   O
in   O   O
SPSS   O   O
to   O   O
assess   O   O
the   O   O
between   O   O
and   O   O
within-subject   O   O
variability   O   O
using   O   O
a   O   O
two-way   O   O
mixed   O   O
effects   O   O
model   O   O
with   O   O
absolute   O   O
agreement   O   O
,   O   O
single   O   O
measurement   O   O
criteria   O   O
,   O   O
also   O   O
known   O   O
as   O   O
ICC   O   O
(   O   O
3,1   O   O
)   O   O
model   O   O
.   O   O
ICCs   O   O
were   O   O
calculated   O   O
for   O   O
multiple   O   O
rest   O   O
iterations   O   O
:   O   O
for   O   O
each   O   O
visit   O   O
(   O   O
across   O   O
one   O   O
hour   O   O
)   O   O
,   O   O
for   O   O
each   O   O
task   O   O
(   O   O
across   O   O
one   O   O
week   O   O
)   O   O
and   O   O
for   O   O
all   O   O
runs   O   O
.   O   O
ICCs   O   O
ranged   O   O
from   O   O
0   O   O
to   O   O
1   O   O
(   O   O
negative   O   O
values   O   O
scored   O   O
as   O   O
zero   O   O
)   O   O
with   O   O
higher   O   O
values   O   O
indicating   O   O
better   O   O
reliability   O   O
.   O   O
Following   O   O
the   O   O
guidelines   O   O
of   O   O
we   O   O
defined   O   O
ICCs   O   O
as   O   O
:   O   O
excellent   O   O
reliability   O   O
>   O   O
0.75   O   O
,   O   O
good   O   O
reliability   O   O
0.75   O   O
–   O   O
0.60   O   O
,   O   O
fair   O   O
reliability   O   O
0.59   O   O
–   O   O
0.40   O   O
,   O   O
and   O   O
poor   O   O
reliability   O   O
<   O   O
0.40   O   O
.   O   O
Statistical   O   O
Analysis   O   O
All   O   O
statistics   O   O
were   O   O
performed   O   O
using   O   O
SPSS   O   O
(   O   O
version   O   O
25   O   O
for   O   O
Macintosh   O   O
)   O   O
.   O   O
Mixed   O   O
Effect   O   O
Repeated   O   O
Measures-Analysis   O   O
of   O   O
Variance   O   O
(   O   O
RM-ANOVAs   O   O
)   O   O
had   O   O
statistical   O   O
thresholds   O   O
set   O   O
at   O   O
p   O   O
<   O   O
0.05   O   O
.   O   O
Greenhouse-Geisser   O   O
corrections   O   O
were   O   O
made   O   O
for   O   O
sphericity   O   O
violations   O   O
.   O   O
The   O   O
between-subject   O   O
factor   O   O
was   O   O
Group   O   O
(   O   O
HC   O   O
,   O   O
SZ   O   O
)   O   O
,   O   O
within-subject   O   O
factors   O   O
included   O   O
Hemisphere   O   O
(   O   O
Left   O   O
,   O   O
Right   O   O
)   O   O
,   O   O
Resting-State   O   O
(   O   O
EO   O   O
,   O   O
EC   O   O
)   O   O
,   O   O
and   O   O
/   O   O
or   O   O
Region   O   O
[   O   O
Superior   O   O
Parietal   O   O
(   O   O
SupPar   O   O
)   O   O
,   O   O
Inferior   O   O
Parietal   O   O
(   O   O
InfPar   O   O
)   O   O
,   O   O
Precuneus   O   O
]   O   O
depending   O   O
on   O   O
measure   O   O
explored   O   O
.   O   O
Significant   O   O
interactions   O   O
were   O   O
followed-up   O   O
with   O   O
separate   O   O
one-way   O   O
ANOVAs   O   O
,   O   O
or   O   O
t-tests   O   O
on   O   O
the   O   O
factors   O   O
of   O   O
interest   O   O
with   O   O
familywise   O   O
multiple   O   O
comparisons   O   O
correction   O   O
using   O   O
false   O   O
discovery   O   O
rate   O   O
(   O   O
FDR   O   O
)   O   O
correction   O   O
with   O   O
q   O   O
=   O   O
0.05   O   O
.   O   O
Alcohol   O   O
effects   O   O
on   O   O
globus   O   O
pallidus   O   O
connectivity   O   O
:   O   O
Role   O   O
of   O   O
impulsivity   O   O
and   O   O
binge   O   O
drinking   O   O
Despite   O   O
the   O   O
harm   O   O
caused   O   O
by   O   O
binge   O   O
drinking   O   O
,   O   O
the   O   O
neural   O   O
mechanisms   O   O
leading   O   O
to   O   O
risky   O   O
and   O   O
disinhibited   O   O
intoxication-related   O   O
behaviors   O   O
are   O   O
not   O   O
well   O   O
understood   O   O
.   O   O
Evidence   O   O
suggests   O   O
that   O   O
the   O   O
globus   O   O
pallidus   O   O
externus   O   O
(   O   O
GPe   O   O
)   O   O
,   O   O
a   O   O
substructure   O   O
within   O   O
the   O   O
basal   O   O
ganglia   O   O
,   O   O
participates   O   O
in   O   O
inhibitory   O   O
control   O   O
processes   O   O
,   O   O
as   O   O
examined   O   O
in   O   O
stop-signaling   O   O
tasks   O   O
.   O   O
In   O   O
fact   O   O
,   O   O
studies   O   O
in   O   O
rodents   O   O
have   O   O
revealed   O   O
that   O   O
alcohol   O   O
can   O   O
change   O   O
GPe   O   O
activity   O   O
by   O   O
decreasing   O   O
neuronal   O   O
firing   O   O
rates   O   O
,   O   O
suggesting   O   O
that   O   O
the   O   O
GPe   O   O
may   O   O
have   O   O
a   O   O
central   O   O
role   O   O
in   O   O
explaining   O   O
impulsive   O   O
behaviors   O   O
and   O   O
failures   O   O
of   O   O
inhibition   O   O
that   O   O
occur   O   O
during   O   O
binge   O   O
drinking   O   O
.   O   O
In   O   O
this   O   O
study   O   O
,   O   O
twenty-five   O   O
healthy   NoKnownDisorder   O
volunteers   NoKnownDisorder   O
underwent   O   O
intravenous   O   O
alcohol   O   O
infusion   O   O
to   O   O
achieve   O   O
a   O   O
blood   O   O
alcohol   O   O
level   O   O
of   O   O
0.08   O   O
g   O   O
/   O   O
dl   O   O
,   O   O
which   O   O
is   O   O
equivalent   O   O
to   O   O
a   O   O
binge   O   O
drinking   O   O
episode   O   O
.   O   O
A   O   O
resting   RestingStateImaging   FunctionalMagneticResonanceImaging
state   RestingStateImaging   FunctionalMagneticResonanceImaging
functional   RestingStateImaging   FunctionalMagneticResonanceImaging
magnetic   RestingStateImaging   FunctionalMagneticResonanceImaging
resonance   RestingStateImaging   FunctionalMagneticResonanceImaging
imaging   O   FunctionalMagneticResonanceImaging
scan   O   FunctionalMagneticResonanceImaging
was   O   O
collected   O   O
prior   O   O
to   O   O
the   O   O
infusion   O   O
and   O   O
at   O   O
binge-level   O   O
exposure   O   O
.   O   O
Functional   O   O
connectivity   O   O
analysis   O   O
was   O   O
used   O   O
to   O   O
investigate   O   O
the   O   O
association   O   O
between   O   O
alcohol-induced   O   O
changes   O   O
in   O   O
GPe   O   O
connectivity   O   O
,   O   O
drinking   O   O
behaviors   O   O
,   O   O
and   O   O
impulsivity   O   O
traits   O   O
.   O   O
We   O   O
found   O   O
that   O   O
individuals   NondependentAlcoholAbuse   O
with   NondependentAlcoholAbuse   O
greater   NondependentAlcoholAbuse   O
number   NondependentAlcoholAbuse   O
of   NondependentAlcoholAbuse   O
drinks   NondependentAlcoholAbuse   O
or   NondependentAlcoholAbuse   O
heavy   NondependentAlcoholAbuse   O
drinking   NondependentAlcoholAbuse   O
days   NondependentAlcoholAbuse   O
in   O   O
the   O   O
recent   O   O
past   O   O
had   O   O
greater   O   O
alcohol-induced   O   O
deficits   O   O
in   O   O
GPe   O   O
connectivity   O   O
,   O   O
particularly   O   O
to   O   O
the   O   O
striatum   O   O
.   O   O
Our   O   O
data   O   O
also   O   O
indicated   O   O
an   O   O
association   O   O
between   O   O
impulsivity   O   O
and   O   O
alcohol-induced   O   O
deficits   O   O
in   O   O
GPe—frontal   O   O
/   O   O
precentral   O   O
connectivity   O   O
.   O   O
Moreover   O   O
,   O   O
alcohol   O   O
induced   O   O
changes   O   O
in   O   O
GPe-amygdala   O   O
circuitry   O   O
suggested   O   O
greater   O   O
vulnerabilities   O   O
to   O   O
stress-related   O   O
drinking   O   O
in   O   O
some   O   O
individuals   O   O
.   O   O
Taken   O   O
together   O   O
,   O   O
these   O   O
findings   O   O
suggest   O   O
that   O   O
alcohol   O   O
may   O   O
interact   O   O
with   O   O
impulsive   O   O
personality   O   O
traits   O   O
and   O   O
drinking   O   O
patterns   O   O
to   O   O
drive   O   O
alterations   O   O
in   O   O
GPe   O   O
circuitry   O   O
associated   O   O
with   O   O
behavioral   O   O
inhibition   O   O
,   O   O
possibly   O   O
indicating   O   O
a   O   O
neural   O   O
mechanism   O   O
by   O   O
which   O   O
binge   O   O
drinking   O   O
could   O   O
lead   O   O
to   O   O
impulsive   O   O
behaviors   O   O
.   O   O
Methods   StudyMethod   StudyMethod
This   O   O
study   O   O
was   O   O
approved   O   O
by   O   O
the   O   O
NIH   O   O
Addictions   O   O
Institutional   O   EstimationAnalysis
Review   O   O
Board   O   O
under   O   O
12   O   O
-   O   O
AA   O   O
-   O   O
0032   O   O
.   O   O
All   O   O
subjects   O   O
provided   O   O
written   O   O
informed   O   O
consent   O   O
prior   O   O
to   O   O
their   O   O
participation   O   O
in   O   O
the   O   O
study   O   O
.   O   O
Participants   O   O
Twenty-five   O   O
healthy   NoKnownDisorder   O
(   NoKnownDisorder   O
13   NoKnownDisorder   O
males   NoKnownDisorder   O
,   NoKnownDisorder   O
12   NoKnownDisorder   O
females   NoKnownDisorder   O
;   NoKnownDisorder   O
mean   NoKnownDisorder   O
age   NoKnownDisorder   O
:   NoKnownDisorder   O
28.85   NoKnownDisorder   O
years   NoKnownDisorder   O
)   NoKnownDisorder   O
,   NoKnownDisorder   O
light   NoKnownDisorder   O
social   NoKnownDisorder   O
drinkers   NoKnownDisorder   O
were   O   O
recruited   O   O
by   O   O
local   O   O
advertisement   O   O
,   O   O
according   O   O
to   O   O
approved   O   O
National   O   O
Institutes   O   O
of   O   O
Health   O   O
Institutional   O   O
Review   O   O
Board   O   O
procedures   O   O
.   O   O
The   O   O
demographic   O   O
data   O   O
of   O   O
participants   O   O
is   O   O
summarized   O   O
in   O   O
Table   O   O
1   O   O
.   O   O
After   O   O
obtaining   O   O
written   O   O
informed   O   O
consent   O   O
,   O   O
all   O   O
participants   O   O
underwent   O   O
a   O   O
comprehensive   O   O
medical   O   O
screen   O   O
,   O   O
including   O   O
blood   O   O
work   O   O
,   O   O
urinalysis   O   O
,   O   O
medical   O   O
history   O   O
,   O   O
physical   O   O
exam   O   O
,   O   O
and   O   O
a   O   O
Structured   StructuredClinicalInterviewforDSMDisorders   O
Clinical   StructuredClinicalInterviewforDSMDisorders   O
Interview   StructuredClinicalInterviewforDSMDisorders   O
for   StructuredClinicalInterviewforDSMDisorders   O
the   StructuredClinicalInterviewforDSMDisorders   O
DSM   StructuredClinicalInterviewforDSMDisorders   O
Axis-I   StructuredClinicalInterviewforDSMDisorders   MoodDisorder
Disorders   StructuredClinicalInterviewforDSMDisorders   MoodDisorder
(   StructuredClinicalInterviewforDSMDisorders   MoodDisorder
SCID-IV   StructuredClinicalInterviewforDSMDisorders   MoodDisorder
)   StructuredClinicalInterviewforDSMDisorders   MoodDisorder
.   StructuredClinicalInterviewforDSMDisorders   O
Criteria   O   O
for   O   O
inclusion   O   O
in   O   O
this   O   O
study   O   O
were   O   O
:   O   O
healthy   O   O
,   O   O
21   O   O
–   O   O
45   O   O
years   O   O
old   O   O
,   O   O
consumption   DrinkingEpisode   O
of   DrinkingEpisode   O
1   DrinkingEpisode   O
to   DrinkingEpisode   O
10   DrinkingEpisode   O
drinks   DrinkingEpisode   O
per   DrinkingEpisode   O
week   DrinkingEpisode   O
for   DrinkingEpisode   O
females   DrinkingEpisode   O
and   DrinkingEpisode   O
1   DrinkingEpisode   O
to   DrinkingEpisode   O
14   DrinkingEpisode   O
drinks   DrinkingEpisode   O
per   DrinkingEpisode   O
week   DrinkingEpisode   O
for   DrinkingEpisode   O
males   DrinkingEpisode   O
.   O   O
Subjects   DrinkingSession   O
also   DrinkingSession   O
had   DrinkingSession   O
to   DrinkingSession   O
have   DrinkingSession   O
consumed   DrinkingSession   O
at   DrinkingSession   O
least   DrinkingSession   O
two   DrinkingSession   O
standard   DrinkingSession   O
drinks   DrinkingSession   O
of   DrinkingSession   O
alcohol   DrinkingSession   O
within   DrinkingSession   O
one   DrinkingSession   O
hour   DrinkingSession   O
on   DrinkingSession   O
at   DrinkingSession   O
least   DrinkingSession   O
one   DrinkingSession   O
occasion   DrinkingSession   O
in   DrinkingSession   O
their   DrinkingSession   O
lifetime   DrinkingSession   O
.   O   O
Criteria   O   O
for   O   O
exclusion   O   O
included   O   O
:   O   O
abnormal   O   O
blood   O   O
or   O   O
urine   O   O
lab   O   O
test   O   O
values   O   O
or   O   O
findings   O   O
from   O   O
the   O   O
medical   O   O
screen   O   O
,   O   O
DSM-IV   O   O
criteria   O   O
for   O   O
alcohol   O   O
or   O   O
other   O   O
substance   O   O
dependence   O   O
(   O   O
excluding   O   O
nicotine   O   O
)   O   O
at   O   O
any   O   O
time   O   O
;   O   O
current   O   O
or   O   O
past   O   O
major   O   O
psychiatric   O   O
disorder   O   O
(   O   O
DSM-IV   O   O
Axis   O   O
I   O   O
)   O   O
,   O   O
head   O   O
injury   O   O
requiring   O   O
hospitalization   O   O
,   O   O
Body   O   O
Mass   O   O
Index   O   O
(   O   O
BMI   O   O
)   O   O
value   O   O
over   O   O
30   O   O
,   O   O
inability   O   O
to   O   O
stop   O   O
taking   O   O
any   O   O
medication   O   O
or   O   O
drugs   O   O
3   O   O
days   O   O
prior   O   O
to   O   O
study   O   O
days   O   O
,   O   O
and   O   O
MRI   O   O
contraindications   O   O
.   O   O
Also   O   O
,   O   O
non-drinkers   O   O
were   O   O
excluded   O   O
from   O   O
the   O   O
study   O   O
due   O   O
to   O   O
ethical   O   O
concerns   O   O
related   O   O
to   O   O
alcohol   O   O
administration   O   O
.   O   O
Demographic   O   O
,   O   O
drinking   O   O
,   O   O
and   O   O
impulsivity   O   O
characteristics   O   O
.   O   O
Variable   O   O
Count   O   O
Total   O   O
n   O   O
25   O   O
Gender   O   O
(   O   O
Male   O   O
/   O   O
Female   O   O
)   O   O
13   O   O
/   O   O
12   O   O
Smokers   O   O
1   O   O
Mean   O   O
SD   O   O
Age   O   O
28.85   O   O
7.40   O   O
Years   O   O
Of   O   O
Education   O   O
15.88   O   O
1.88   O   O
BIS   O   O
:   O   O
Total   O   O
54.76   O   O
9.62   O   O
Attentional   O   O
Impulsiveness   O   BarrattImpulsivenessQuestionnaire
12.96   O   O
2.99   O   O
Motor   O   O
Impulsiveness   O   O
20.92   O   O
3.32   O   O
Nonplanning   O   O
Impulsiveness   O   BarrattImpulsivenessQuestionnaire
19.72   O   O
4.21   O   O
UPPS-P   O   O
:   O   O
Positive   O   O
Urgency   O   O
1.36   O   O
0.31   O   O
Negative   O   O
Urgency   O   O
1.66   O   O
0.44   O   O
Premeditation   O   O
1.78   O   O
0.42   O   O
Perseverence   O   O
1.53   O   O
0.39   O   O
Sensation   O   O
Seeking   O   O
2.85   O   O
0.70   O   O
Delay   O   O
Discounting   O   O
Rate   O   O
(   O   O
K   O   O
)   O   O
0.02   O   O
0.06   O   O
TLFB—Drinks   O   O
Per   O   O
Thirty   O   O
Days   O   O
20.19   O   O
13.69   O   O
TLFB—Heavy   O   O
Drinking   O   DrinkingDay
Days   O   O
19.08   O   O
10.96   O   O
Abbreviations   O   O
as   O   O
follow   O   O
:   O   O
BIS   ImpulsivityScale   CannabisAbuse
-   ImpulsivityScale   O
Barratt   ImpulsivityScale   O
Impulsiveness   ImpulsivityScale   ImpulsivityScale
Scale   ImpulsivityScale   ImpulsivityScale
;   O   ImpulsivityScale
TLFB   MentalHealthDiagnosisScale   ImpulsivityScale
-   MentalHealthDiagnosisScale   O
Alcohol   MentalHealthDiagnosisScale   O
Timeline   MentalHealthDiagnosisScale   FollowupDataCollection
Followback   MentalHealthDiagnosisScale   FollowupDataCollection
.   O   FollowupDataCollection
Measures   O   O
Alcohol   O   O
drinking   O   O
measures   O   O
The   O   O
amount   O   O
of   O   O
daily   O   O
alcohol   O   O
consumption   O   O
over   O   O
the   O   O
last   O   O
90   O   O
days   O   O
was   O   O
measured   O   O
using   O   O
the   O   O
Alcohol   AlcoholUseQuestionnaire   AlcoholAbuse
Timeline-Followback   AlcoholUseQuestionnaire   AlcoholAbuse
(   AlcoholUseQuestionnaire   O
TLFB   AlcoholUseQuestionnaire   Thing
)   AlcoholUseQuestionnaire   O
calendar—a   O   O
drinking   O   O
assessment   O   O
method   O   O
with   O   O
good   O   O
psychometric   O   O
characteristics   O   O
for   O   O
estimating   O   O
retrospective   O   O
daily   O   O
drinking   O   O
patterns   O   O
.   O   O
The   O   O
number   O   O
of   O   O
heavy   O   O
drinking   O   O
days   O   O
in   O   O
the   O   O
last   O   O
90   O   O
days   O   O
was   O   O
calculated   O   O
from   O   O
the   O   O
TLFB   AlcoholUseQuestionnaire   O
;   O   O
a   O   O
heavy   O   O
drinking   O   O
day   O   O
is   O   O
defined   O   O
as   O   O
4   O   O
or   O   O
more   O   O
drinks   O   O
per   O   O
day   O   O
for   O   O
women   O   O
and   O   O
5   O   O
or   O   O
more   O   O
drinks   O   O
per   O   O
day   O   O
for   O   O
men   O   O
.   O   O
We   O   O
used   O   O
this   O   O
as   O   O
a   O   O
measure   O   O
for   O   O
binge   DrinkingBinge   O
drinking   DrinkingBinge   O
.   O   O
Total   O   O
drinks   O   O
in   O   O
the   O   O
past   O   O
30   O   O
days   O   O
was   O   O
also   O   O
calculated   O   O
from   O   O
the   O   O
TLFB   AlcoholUseQuestionnaire   O
.   O   O
Past   DrinkingDay   O
30   DrinkingDay   O
-   DrinkingDay   O
day   DrinkingDay   O
drinking   DrinkingDay   O
was   DrinkingDay   O
used   DrinkingDay   O
rather   DrinkingDay   O
than   DrinkingDay   O
90   DrinkingDay   O
-   DrinkingDay   O
day   DrinkingDay   O
drinking   DrinkingDay   O
given   DrinkingDay   O
that   DrinkingDay   O
we   DrinkingDay   O
were   DrinkingDay   O
interested   DrinkingDay   O
in   DrinkingDay   O
recent   DrinkingDay   O
drinking   DrinkingDay   O
,   DrinkingDay   O
and   DrinkingDay   O
that   DrinkingDay   O
recent   DrinkingDay   O
reports   DrinkingDay   O
of   DrinkingDay   O
drinking   DrinkingDay   O
may   DrinkingDay   O
be   DrinkingDay   O
more   DrinkingDay   O
reliable   DrinkingDay   O
.   DrinkingDay   O
Impulsivity   O   O
measures   O   O
Impulsive   O   O
behavioral   O   O
traits   O   O
were   O   O
measured   O   O
using   O   O
the   O   O
Barratt   ImpulsivityScale   BarrattImpulsivenessQuestionnaire
Impulsiveness   ImpulsivityScale   BarrattImpulsivenessQuestionnaire
Scale   ImpulsivityScale   BarrattImpulsivenessQuestionnaire
(   ImpulsivityScale   BarrattImpulsivenessQuestionnaire
BIS   ImpulsivityScale   BarrattImpulsivenessQuestionnaire
-   ImpulsivityScale   BarrattImpulsivenessQuestionnaire
11   ImpulsivityScale   BarrattImpulsivenessQuestionnaire
)   ImpulsivityScale   BarrattImpulsivenessQuestionnaire
and   O   O
the   O   O
UPPS-P   ImpulsivityScale   ImpulsivityScale
Impulsive   ImpulsivityScale   ImpulsivityScale
Behavior   ImpulsivityScale   ImpulsivityScale
Scale   ImpulsivityScale   ImpulsivityScale
,   O   O
two   O   O
of   O   O
the   O   O
most   O   O
widely-used   O   O
self-report   O   O
tools   O   O
in   O   O
the   O   O
evaluation   O   O
of   O   O
trait   O   O
impulsivity   O   O
.   O   O
The   O   O
BIS   ImpulsivityScale   Scale
-   ImpulsivityScale   Scale
11   ImpulsivityScale   Scale
scale   O   Scale
evaluates   O   O
impulsive   O   O
behavior   O   O
in   O   O
general   O   O
,   O   O
and   O   O
the   O   O
motor   O   O
,   O   O
attentional   O   O
and   O   O
non-planning   O   O
sub-scales   O   O
evaluate   O   O
acting   O   O
without   O   O
thinking   O   O
,   O   O
inability   O   O
to   O   O
focus   O   O
attention   O   O
and   O   O
lack   O   O
of   O   O
forethought   O   O
,   O   O
respectively   O   O
.   O   O
The   O   O
UPPS-P   ImpulsivityScale   O
measures   O   O
personality   O   O
traits   O   O
conducive   O   O
to   O   O
impulsive   O   O
behavior   O   O
including   O   O
Urgency   O   O
(   O   O
negative   O   O
)   O   O
—   O   O
tendency   O   O
to   O   O
impulsively   O   O
act   O   O
under   O   O
strong   O   O
negative   O   O
emotions   O   O
,   O   O
Premeditation   O   O
(   O   O
lack   O   O
of   O   O
)   O   O
—   O   O
tendency   O   O
to   O   O
act   O   O
without   O   O
thinking   O   O
,   O   O
Perseverance   O   O
(   O   O
lack   O   O
of   O   O
)   O   O
to   O   O
remain   O   O
focused   O   O
on   O   O
a   O   O
task   O   O
,   O   O
Sensation-seeking—tendency   O   O
to   O   O
seek   O   O
out   O   O
novel   O   O
/   O   O
thrilling   O   O
experiences   O   O
,   O   O
and   O   O
Positive-urgency—tendency   O   O
to   O   O
impulsively   O   O
act   O   O
under   O   O
strong   O   O
positive   O   O
emotions   O   O
.   O   O
We   O   O
also   O   O
evaluated   O   O
choice   O   O
impulsivity   O   O
with   O   O
the   O   O
Delay   ImpulsivityScale   FingerTappingTask
Discounting   ImpulsivityScale   FingerTappingTask
Task   ImpulsivityScale   FingerTappingTask
(   ImpulsivityScale   FingerTappingTask
DDT   ImpulsivityScale   FingerTappingTask
)   ImpulsivityScale   FingerTappingTask
.   O   O
The   O   O
DDT   ImpulsivityScale   O
measures   O   O
impulsivity   O   O
by   O   O
presenting   O   O
the   O   O
subject   O   O
with   O   O
a   O   O
series   O   O
of   O   O
hypothetical   O   O
choices   O   O
between   O   O
receiving   O   O
a   O   O
smaller   O   O
immediate   O   O
monetary   O   O
reward   O   O
or   O   O
a   O   O
larger   O   O
delayed   O   O
reward   O   O
.   O   O
Subjects   O   O
were   O   O
presented   O   O
as   O   O
their   O   O
immediate   O   O
reward   O   O
values   O   O
between   O   O
$100   O   O
and   O   O
$0   O   O
dollars   O   O
in   O   O
increments   O   O
of   O   O
$10   O   O
,   O   O
while   O   O
the   O   O
delayed   O   O
reward   O   O
was   O   O
$100   O   O
.   O   O
Delays   O   O
were   O   O
0   O   O
,   O   O
7   O   O
,   O   O
14   O   O
,   O   O
20   O   O
,   O   O
25   O   O
,   O   O
or   O   O
30   O   O
days   O   O
.   O   O
Subjects   O   O
completed   O   O
trials   O   O
with   O   O
all   O   O
iterations   O   O
of   O   O
these   O   O
parameters   O   O
.   O   O
The   O   O
rate   O   O
of   O   O
discounting   O   O
of   O   O
the   O   O
delayed   O   O
outcome   O   O
(   O   O
k   O   O
)   O   O
was   O   O
calculated   O   O
and   O   O
then   O   O
a   O   O
natural   O   O
log-transformation   O   O
was   O   O
applied   O   O
to   O   O
correct   O   O
for   O   O
the   O   O
non-normal   O   O
distribution   O   O
of   O   O
k   O   O
values   O   O
.   O   O
The   O   O
resulting   O   O
ln   O   O
(   O   O
k   O   O
)   O   O
is   O   O
used   O   O
to   O   O
represent   O   O
delay   O   O
discounting   O   O
,   O   O
where   O   O
higher   O   O
ln   O   O
(   O   O
k   O   O
)   O   O
values   O   O
mean   O   O
greater   O   O
preference   O   O
for   O   O
immediate   O   O
rewards   O   O
(   O   O
see   O   O
Table   O   O
1   O   O
for   O   O
descriptive   O   O
statistics   O   O
of   O   O
drinking   O   O
and   O   O
impulsivity   O   O
scores   O   O
for   O   O
the   O   O
sample   O   O
)   O   O
.   O   O
Experimental   O   O
design   O   O
and   O   O
statistical   O   O
analysis   O   O
Overall   O   O
timeline   O   O
In   O   O
this   O   O
two-session   O   O
study   O   O
,   O   O
healthy   O   O
light   O   O
drinkers   O   O
received   O   O
an   O   O
IV   O   O
alcohol   O   O
infusion   O   O
on   O   O
two   O   O
separate   O   O
days   O   O
.   O   O
The   O   O
first   O   O
session   O   O
was   O   O
conducted   O   O
outside   O   O
the   O   O
scanner   O   O
to   O   O
establish   O   O
the   O   O
alcohol   O   O
infusion   O   O
rate   O   O
profile   O   O
to   O   O
achieve   O   O
and   O   O
maintain   O   O
the   O   O
target   O   O
BrAC   O   O
exposure   O   O
,   O   O
and   O   O
to   O   O
ensure   O   O
tolerability   O   O
.   O   O
The   O   O
alcohol   O   O
infusion   O   O
for   O   O
the   O   O
second   O   O
session   O   O
was   O   O
conducted   O   O
inside   O   O
the   O   O
scanner   O   O
at   O   O
least   O   O
three   O   O
days   O   O
after   O   O
the   O   O
first   O   O
session   O   O
(   O   O
Fig   O   O
1   O   O
)   O   O
.   O   O
Participants   O   O
were   O   O
asked   O   O
to   O   O
fast   O   O
the   O   O
night   O   O
before   O   O
each   O   O
session   O   O
.   O   O
At   O   O
the   O   O
start   O   O
of   O   O
each   O   O
visit   O   O
,   O   O
breath   O   O
alcohol   O   O
levels   O   O
,   O   O
urine   O   O
pregnancy   O   O
tests   O   O
(   O   O
if   O   O
applicable   O   O
)   O   O
and   O   O
urine   O   O
drug   O   O
screens   O   O
were   O   O
collected   O   O
.   O   O
In   O   O
addition   O   O
,   O   O
we   O   O
conducted   O   O
a   O   O
brief   O   O
history   O   O
interview   O   O
about   O   O
recent   O   O
alcohol   O   O
,   O   O
medication   O   O
,   O   O
and   O   O
nicotine   O   O
use   O   O
,   O   O
changes   O   O
in   O   O
physical   O   O
health   O   O
,   O   O
and   O   O
menstruation   O   O
(   O   O
if   O   O
applicable   O   O
)   O   O
.   O   O
Timeline   O   O
of   O   O
intravenous   O   O
alcohol   O   O
infusion   O   O
study   O   O
.   O   O
The   O   O
timeline   O   O
depiction   O   O
of   O   O
the   O   O
two-session   O   O
intravenous   O   O
alcohol   O   O
infusion   O   O
study   O   O
;   O   O
sessions   O   O
were   O   O
separated   O   O
at   O   O
least   O   O
three   O   O
days   O   O
from   O   O
each   O   O
other   O   O
.   O   O
The   O   O
session   O   O
2   O   O
timeline   O   O
indicates   O   O
timepoints   O   O
of   O   O
resting   O   O
state   O   O
and   O   O
BAC   O   O
measurement   O   O
alongside   O   O
IV   O   O
infusion   O   O
;   O   O
the   O   O
first   O   O
resting   O   RestingStateImaging
state   O   RestingStateImaging
scan   O   O
occurred   O   O
before   O   O
the   O   O
IV   O   O
infusion   O   O
at   O   O
blood   O   O
alcohol   O   O
level   O   O
of   O   O
0.0   O   O
g   O   O
/   O   O
dl   O   O
and   O   O
the   O   O
second   O   O
one   O   O
was   O   O
collected   O   O
when   O   O
the   O   O
blood   O   O
alcohol   O   O
level   O   O
reached   O   O
the   O   O
binge   O   O
levels   O   O
(   O   O
0.08   O   O
g   O   O
/   O   O
dl   O   O
)   O   O
.   O   O
Alcohol   O   O
infusion   O   O
to   O   O
binge   O   O
level   O   O
exposure   O   O
We   O   O
performed   O   O
the   O   O
alcohol   O   O
infusion   O   O
procedure   O   O
following   O   O
previously   O   O
published   O   O
methods   O   O
(   O   O
fMRI   FunctionalMagneticResonanceImaging   O
and   O   O
PET   PositronEmissionTomography   O
)   O   O
.   O   O
In   O   O
both   O   O
sessions   O   O
,   O   O
participants   O   O
received   O   O
an   O   O
intravenous   O   O
(   O   O
IV   O   O
)   O   O
infusion   O   O
of   O   O
6%   O   O
v   O   O
/   O   O
v   O   O
ethanol   O   O
solution   O   O
in   O   O
saline   O   O
to   O   O
achieve   O   O
a   O   O
target   O   O
breath   O   O
alcohol   O   O
concentration   O   O
(   O   O
BrAC   O   O
)   O   O
of   O   O
0.08   O   O
±   O   O
0.005   O   O
g   O   O
/   O   O
dl   O   O
at   O   O
15   O   O
min   O   O
after   O   O
the   O   O
start   O   O
of   O   O
the   O   O
infusion   O   O
,   O   O
and   O   O
to   O   O
maintain   O   O
(   O   O
or   O   O
clamp   O   O
)   O   O
the   O   O
target   O   O
BrAC   O   O
level   O   O
for   O   O
30   O   O
min   O   O
(   O   O
Fig   O   O
1   O   O
)   O   O
.   O   O
The   O   O
infusion-rate   O   O
profile   O   O
was   O   O
computed   O   O
for   O   O
each   O   O
subject   O   O
using   O   O
a   O   O
physiologically-based   O   O
pharmacokinetic   O   O
(   O   O
PBPK   O   O
)   O   O
model-based   O   O
algorithm   O   O
,   O   O
with   O   O
individualized   O   O
estimates   O   O
of   O   O
the   O   O
model   O   O
parameters   O   O
estimated   O   O
from   O   O
the   O   O
subject   O   O
’   O   O
s   O   O
height   O   O
,   O   O
weight   O   O
,   O   O
age   O   O
and   O   O
sex   O   O
.   O   O
During   O   O
the   O   O
first   O   O
session   O   O
conducted   O   O
outside   O   O
the   O   O
scanner   O   O
,   O   O
serial   O   O
BrACs   O   O
were   O   O
measured   O   O
at   O   O
frequent   O   O
intervals   O   O
(   O   O
5   O   O
–   O   O
15   O   O
minutes   O   O
)   O   O
using   O   O
the   O   O
Alcotest   O   O
7410   O   O
+   O   O
handheld   O   O
breathalyzer   O   O
(   O   O
Drager   O   O
Safety   O   O
Inc   O   O
.   O   O
,   O   O
CO   O   O
)   O   O
,   O   O
to   O   O
ensure   O   O
that   O   O
each   O   O
BrAC   O   O
was   O   O
within   O   O
0.005   O   O
g   O   O
/   O   O
dl   O   O
of   O   O
the   O   O
target   O   O
,   O   O
and   O   O
to   O   O
enable   O   O
minor   O   O
adjustments   O   O
to   O   O
the   O   O
infusion   O   O
rates   O   O
to   O   O
overcome   O   O
errors   O   O
in   O   O
parameter   O   O
estimation   O   O
and   O   O
experimental   O   O
variability   O   O
.   O   O
The   O   O
adjusted   O   O
infusion   O   O
rate   O   O
profile   O   O
from   O   O
the   O   O
first   O   O
session   O   O
was   O   O
used   O   O
in   O   O
the   O   O
imaging   O   O
session   O   O
to   O   O
replicate   O   O
the   O   O
target   O   O
BrAC   O   O
profile   O   O
for   O   O
each   O   O
subject   O   O
.   O   O
This   O   O
approach   O   O
has   O   O
been   O   O
used   O   O
to   O   O
successfully   O   O
achieve   O   O
and   O   O
maintain   O   O
target   O   O
BrACs   O   O
,   O   O
as   O   O
verified   O   O
by   O   O
blood   O   O
alcohol   O   O
concentrations   O   O
measured   O   O
in   O   O
samples   O   O
drawn   O   O
during   O   O
the   O   O
scan   O   O
in   O   O
other   O   O
neuroimaging   O   O
studies   O   O
.   O   O
After   O   O
the   O   O
end   O   O
of   O   O
the   O   O
infusion   O   O
,   O   O
subjects   O   O
were   O   O
provided   O   O
a   O   O
meal   O   O
,   O   O
and   O   O
BrAC   O   O
was   O   O
tracked   O   O
until   O   O
it   O   O
dropped   O   O
to   O   O
0.02   O   O
g   O   O
/   O   O
dL   O   O
or   O   O
below   O   O
,   O   O
at   O   O
which   O   O
time   O   O
subjects   O   O
were   O   O
taken   O   O
home   O   O
by   O   O
a   O   O
designated   O   O
driver   O   O
or   O   O
taxi   O   O
.   O   O
Neuroimaging   O   O
acquisition   O   O
and   O   O
preprocessing   O   O
During   O   O
session   O   O
2   O   O
,   O   O
after   O   O
the   O   O
IV   O   O
catheters   O   O
were   O   O
placed   O   O
for   O   O
alcohol   O   O
infusion   O   O
,   O   O
participants   O   O
were   O   O
placed   O   O
in   O   O
a   O   O
3T   O   O
SIEMENS   O   O
Skyra   O   O
MR   O   O
scanner   O   O
at   O   O
the   O   O
NMR   O   O
Research   O   O
Center   O   O
at   O   O
the   O   O
NIH   O   O
.   O   O
Before   O   O
starting   O   O
the   O   O
IV   O   O
infusion   O   O
of   O   O
alcohol   O   O
,   O   O
a   O   O
5   O   O
-   O   O
min   O   O
closed   RestingStateImaging   RestingStateImaging
eyes   RestingStateImaging   RestingStateImaging
resting-state   RestingStateImaging   RestingStateImaging
fMRI   RestingStateImaging   RestingStateImaging
scan   O   RestingStateImaging
was   O   O
acquired   O   O
with   O   O
an   O   O
echo-planar   O   O
imaging   O   RestingStateImaging
sequence   O   RestingStateImaging
(   O   O
36   O   O
axial   O   O
slices   O   O
,   O   O
3.8   O   O
mm   O   O
thickness   O   O
,   O   O
64   O   O
×   O   O
64   O   O
matrix   O   O
and   O   O
repetition   O   O
time   O   O
of   O   O
2000   O   O
ms   O   O
,   O   O
echo   O   O
time   O   O
30   O   O
,   O   O
flip   O   O
angle   O   O
90   O   O
)   O   O
.   O   O
After   O   O
collecting   O   O
this   O   O
baseline   O   RestingStateImaging
resting-state   RestingStateImaging   RestingStateImaging
fMRI   RestingStateImaging   RestingStateImaging
scan   O   RestingStateImaging
,   O   O
the   O   O
alcohol   O   O
infusion   O   O
started   O   O
and   O   O
once   O   O
the   O   O
target   O   O
BAC   O   O
was   O   O
achieved   O   O
,   O   O
a   O   O
10   O   O
-   O   O
minute   O   O
waiting   O   O
period   O   O
was   O   O
allowed   O   O
to   O   O
ensure   O   O
the   O   O
BAC   O   O
was   O   O
stable   O   O
at   O   O
the   O   O
0.08   O   O
g   O   O
/   O   O
dl   O   O
level   O   O
.   O   O
During   O   O
the   O   O
waiting   O   O
period   O   O
,   O   O
whole-brain   StructuralImaging   O
structural   StructuralImaging   O
and   O   O
diffusion-weighted   DiffusionWeightedImaging   O
images   DiffusionWeightedImaging   O
of   O   O
the   O   O
brain   O   O
were   O   O
collected   O   O
.   O   O
Then   O   O
,   O   O
a   O   O
second   O   O
eyes-closed   RestingStateImaging   RestingStateImaging
resting-state   RestingStateImaging   RestingStateImaging
fMRI   RestingStateImaging   RestingStateImaging
scan   O   RestingStateImaging
was   O   O
collected   O   O
while   O   O
the   O   O
target   O   O
BAC   O   O
(   O   O
0.08   O   O
g   O   O
/   O   O
dl   O   O
)   O   O
was   O   O
maintained   O   O
.   O   O
Following   O   O
the   O   O
MRI   RestingStateImaging   O
session   O   O
,   O   O
the   O   O
Drug   Questionnaire   BiphasicAlcoholEffectsScale
Effects   Questionnaire   BiphasicAlcoholEffectsScale
Questionnaire   Questionnaire   O
was   O   O
used   O   O
to   O   O
evaluate   O   O
and   O   O
quantify   O   O
subjective   O   O
effects   O   O
of   O   O
alcohol   O   O
(   O   O
DEQ   O   O
)   O   O
.   O   O
CONN   O   O
ver   O   O
.17f   O   O
(   O   O
http   O   O
:   O   O
/   O   O
/   O   O
www.conn-toolbox.org   O   O
)   O   O
,   O   O
a   O   O
MATLAB   O   O
/   O   O
SPM-based   O   O
(   O   O
www.fil.ion.ucl.ac.uk   O   O
/   O   O
spm   O   O
/   O   O
)   O   O
software   O   O
,   O   O
was   O   O
used   O   O
to   O   O
conduct   O   O
spatial   O   O
/   O   O
temporal   O   O
preprocessing   O   O
and   O   O
analyses   O   O
.   O   O
Spatial   O   O
preprocessing   O   O
included   O   O
slice-timing   O   O
correction   O   O
,   O   O
realignment   O   O
,   O   O
co-registration   O   O
,   O   O
normalization   O   O
,   O   O
and   O   O
spatial   O   O
smoothing   O   O
(   O   O
8   O   O
mm   O   O
)   O   O
.   O   O
Using   O   O
the   O   O
default   O   O
settings   O   O
in   O   O
CONN   O   O
,   O   O
images   O   O
were   O   O
resliced   O   O
into   O   O
isotropic   O   O
2mm   O   O
voxels   O   O
.   O   O
Anatomical   O   O
volumes   O   O
were   O   O
segmented   O   O
into   O   O
grey   O   O
matter   O   O
,   O   O
white   O   O
matter   O   O
,   O   O
and   O   O
cerebrospinal   O   O
fluid   O   O
(   O   O
CSF   O   O
)   O   O
areas   O   O
and   O   O
the   O   O
resulting   O   O
masks   O   O
were   O   O
eroded   O   O
to   O   O
minimize   O   O
partial   O   O
volume   O   O
effects   O   O
.   O   O
At   O   O
the   O   O
individual   O   O
level   O   O
,   O   O
the   O   O
temporal   O   O
timeseries   O   O
of   O   O
the   O   O
participant-specific   O   O
six   O   O
rotation-translation   O   O
motion   O   O
parameters   O   O
and   O   O
the   O   O
timeseries   O   O
from   O   O
within   O   O
the   O   O
white   O   O
matter   O   O
/   O   O
CSF   O   O
masks   O   O
were   O   O
used   O   O
as   O   O
temporal   O   O
covariates   O   O
,   O   O
and   O   O
removed   O   O
from   O   O
the   O   O
blood   O   O
oxygen   O   O
level-dependent   O   O
(   O   O
BOLD   O   O
)   O   O
functional   O   O
data   O   O
using   O   O
linear   O   O
regression   O   O
.   O   O
The   O   O
resulting   O   O
residual   O   O
BOLD   O   O
timeseries   O   O
were   O   O
band-pass   O   O
filtered   O   O
(   O   O
0.008Hz   O   O
<   O   O
f   O   O
<   O   O
0.15Hz   O   O
)   O   O
.   O   O
Neuroimaging   O   O
analysis   O   O
To   O   O
our   O   O
knowledge   O   O
there   O   O
is   O   O
no   O   O
reported   O   O
sub-division   O   O
of   O   O
human   O   O
GPe   O   O
with   O   O
concrete   O   O
landmark   O   O
definition   O   O
and   O   O
/   O   O
or   O   O
Talairach   O   O
coordinate   O   O
demarcation   O   O
.   O   O
Therefore   O   O
,   O   O
for   O   O
these   O   O
analyses   O   O
,   O   O
we   O   O
used   O   O
right   O   O
and   O   O
left   O   O
GPe   O   O
masks   O   O
obtained   O   O
from   O   O
the   O   O
Lead-DBS   O   O
toolbox   O   O
(   O   O
http   O   O
:   O   O
/   O   O
/   O   O
www.lead-dbs.org   O   O
/   O   O
)   O   O
.   O   O
These   O   O
anatomical   O   O
masks   O   O
were   O   O
generated   O   O
using   O   O
manual   O   O
tracing   O   O
of   O   O
several   O   O
structural   O   O
MRIs   O   O
and   O   O
subsequent   O   O
co-registration   O   O
with   O   O
histological   O   O
studies   O   O
,   O   O
and   O   O
have   O   O
a   O   O
combined   O   O
volume   O   O
of   O   O
approximately   O   O
929   O   O
mm3   O   O
.   O   O
Seed-based   O   O
correlations   O   O
were   O   O
calculated   O   O
as   O   O
Fisher-transformed   O   O
bivariate   O   O
correlation   O   O
coefficients   O   O
between   O   O
the   O   O
BOLD   O   O
activity   O   O
timeseries   O   O
in   O   O
the   O   O
seed   O   O
ROI   O   O
and   O   O
each   O   O
other   O   O
individual   O   O
voxel   O   O
BOLD   O   O
.   O   O
CSF   O   O
,   O   O
grey   O   O
matter   O   O
,   O   O
white   O   O
matter   O   O
signals   O   O
and   O   O
motion   O   O
were   O   O
included   O   O
as   O   O
covariates   O   O
for   O   O
this   O   O
model   O   O
at   O   O
the   O   O
single   O   O
subject   O   O
level   O   O
.   O   O
These   O   O
correlations   O   O
were   O   O
calculated   O   O
separately   O   O
for   O   O
the   O   O
pre-infusion   O   O
and   O   O
post-infusion   O   O
scans   O   O
and   O   O
for   O   O
right   O   O
and   O   O
left   O   O
GPe   O   O
seeds   O   O
.   O   O
For   O   O
each   O   O
of   O   O
the   O   O
pre   O   O
-   O   O
and   O   O
post-infusion   O   O
analyses   O   O
,   O   O
150   O   O
time   O   O
points   O   O
(   O   O
across   O   O
300   O   O
seconds   O   O
)   O   O
were   O   O
used   O   O
.   O   O
To   O   O
examine   O   O
group   O   O
level   O   O
effects   O   O
,   O   O
the   O   O
resulting   O   O
single-subject   O   O
connectivity   O   O
maps   O   O
were   O   O
used   O   O
as   O   O
input   O   O
for   O   O
second   O   O
level   O   O
analyses   O   O
in   O   O
a   O   O
general   O   O
linear   O   O
model   O   O
.   O   O
We   O   O
modeled   O   O
the   O   O
within-subject   O   O
effect   O   O
of   O   O
timepoint   O   O
(   O   O
i.e   O   O
.   O   O
,   O   O
post   O   O
-   O   O
versus   O   O
pre-alcohol   O   O
infusion   O   O
;   O   O
see   O   O
S1   O   O
File   O   O
,   O   O
S1   O   O
Fig   O   O
and   O   O
S1   O   O
Table   O   O
for   O   O
report   O   O
of   O   O
the   O   O
main   O   O
effects   O   O
of   O   O
alcohol   O   O
administration   O   O
)   O   O
and   O   O
between-subject   O   O
effects   O   O
of   O   O
impulsivity   O   O
(   O   O
BIS   O   O
-   O   O
11   O   Thing
,   O   O
UPPS-P   O   O
,   O   O
and   O   O
DDT   O   O
)   O   O
and   O   O
recent   O   O
drinking   O   O
behaviors   O   O
(   O   O
number   O   O
of   O   O
drinks   O   O
in   O   O
the   O   O
last   O   O
30   O   O
days   O   O
,   O   O
number   O   O
of   O   O
heavy   O   O
drinking   O   O
days   O   O
)   O   O
.   O   O
S1   O   O
Table   O   O
indicates   O   O
clusters   O   O
identified   O   O
as   O   O
showing   O   O
significant   O   O
changes   O   O
from   O   O
pre   O   O
to   O   O
post   O   O
alcohol   O   O
infusion   O   O
,   O   O
as   O   O
well   O   O
as   O   O
associated   O   O
statistics   O   O
.   O   O
For   O   O
the   O   O
seed-to-voxel   O   O
analysis   O   O
,   O   O
reported   O   O
clusters   O   O
survived   O   O
a   O   O
height   O   O
threshold   O   O
of   O   O
uncorrected   O   O
p   O   O
<   O   O
0.001   O   O
with   O   O
a   O   O
cluster   O   O
level   O   O
extent   O   O
threshold   O   O
of   O   O
FDR-corrected   O   O
p   O   O
<   O   O
0.05   O   O
.   O   O
In   O   O
Figs   O   O
3   O   O
–   O   O
5   O   O
,   O   O
these   O   O
clusters   O   O
are   O   O
shown   O   O
overlaid   O   O
on   O   O
structural   O   O
brain   O   O
cutaways   O   O
.   O   O
Corresponding   O   O
line   O   O
plots   O   O
are   O   O
only   O   O
for   O   O
visual   O   O
interpretation   O   O
of   O   O
these   O   O
effects   O   O
.   O   O
We   O   O
also   O   O
examined   O   O
sex   O   O
effects   O   O
on   O   O
alcohol-related   O   O
changes   O   O
in   O   O
GPe   O   O
connectivity   O   O
at   O   O
the   O   O
whole   O   O
brain   O   O
level   O   O
;   O   O
there   O   O
were   O   O
no   O   O
significant   O   O
differences   O   O
between   O   O
males   O   O
and   O   O
females   O   O
.   O   O
In   O   O
order   O   O
to   O   O
test   O   O
our   O   O
hypothesis   O   O
that   O   O
the   O   O
interaction   O   O
between   O   O
recent   O   O
drinking   O   O
behaviors   O   O
and   O   O
impulsivity   O   O
would   O   O
contribute   O   O
to   O   O
alcohol-induced   O   O
changes   O   O
in   O   O
GPe   O   O
functional   O   O
connectivity   O   O
,   O   O
we   O   O
extracted   O   O
ROI-to-voxel   O   O
correlation   O   O
values   O   O
between   O   O
the   O   O
seeds   O   O
and   O   O
significant   O   O
clusters   O   O
and   O   O
used   O   O
those   O   O
values   O   O
to   O   O
conduct   O   O
multiple   O   O
regression   O   O
analysis   O   O
in   O   O
R   O   O
/   O   O
RStudio   O   O
(   O   O
version   O   O
3.4.2   O   O
/   O   O
1.1.383   O   O
)   O   O
.   O   O
We   O   O
modeled   O   O
drinking   O   O
history   O   O
,   O   O
impulsivity   O   O
,   O   O
and   O   O
the   O   O
interaction   O   O
between   O   O
the   O   O
two   O   O
as   O   O
independent   O   O
variables   O   O
on   O   O
the   O   O
dependent   O   O
variable   O   O
of   O   O
change   O   O
in   O   O
GPe   O   O
connectivity   O   O
.   O   O
We   O   O
conducted   O   O
these   O   O
analyses   O   O
only   O   O
for   O   O
significant   O   O
clusters   O   O
identified   O   O
in   O   O
the   O   O
seed-to-voxel   O   O
analysis   O   O
,   O   O
and   O   O
only   O   O
for   O   O
the   O   O
significant   O   O
drinking   O   O
and   O   O
impulsivity   O   O
measures   O   O
.   O   O
For   O   O
the   O   O
drinking   O   O
measures   O   O
identified   O   O
in   O   O
that   O   O
seed-to-voxel   O   O
analysis   O   O
,   O   O
models   O   O
(   O   O
for   O   O
the   O   O
specific   O   O
significant   O   O
cluster   O   O
only   O   O
)   O   O
included   O   O
the   O   O
significant   O   O
drinking   O   O
variable   O   O
as   O   O
well   O   O
as   O   O
one   O   O
of   O   O
the   O   O
two   O   O
significant   O   O
impulsivity   O   O
variables   O   O
;   O   O
thus   O   O
,   O   O
2   O   O
regressions   O   O
per   O   O
cluster   O   O
were   O   O
run   O   O
.   O   O
Similarly   O   O
,   O   O
for   O   O
significant   O   O
impulsivity   O   O
measures   O   O
,   O   O
2   O   O
regressions   O   O
per   O   O
cluster   O   O
were   O   O
run   O   O
(   O   O
as   O   O
there   O   O
are   O   O
two   O   O
drinking   O   O
variables   O   O
)   O   O
.   O   O
This   O   O
resulted   O   O
in   O   O
a   O   O
total   O   O
of   O   O
20   O   O
tests   O   O
.   O   O
We   O   O
then   O   O
adjusted   O   O
the   O   O
omnibus   O   O
test   O   O
statistics   O   O
to   O   O
correct   O   O
for   O   O
multiple   O   O
comparisons   O   O
using   O   O
FDR   O   O
of   O   O
<   O   O
0.05   O   O
.   O   O
Of   O   O
those   O   O
regressions   O   O
,   O   O
only   O   O
those   O   O
with   O   O
significant   O   O
interaction   O   O
effects   O   O
are   O   O
reported   O   O
.   O   O
Disturbances   O   O
across   O   O
whole   O   O
brain   O   O
networks   O   O
during   O   O
reward   O   O
anticipation   O   O
in   O   O
an   O   O
abstinent   O   O
addiction   O   O
population   O   O
Graphical   O   O
abstract   O   O
Network   O   O
based   O   O
statistics   O   O
(   O   O
NBS   O   O
)   O   O
analyses   O   O
detected   O   O
a   O   O
graph   O   O
sub-network   O   O
comprising   O   O
153   O   O
edges   O   O
between   O   O
59   O   O
nodes   O   O
of   O   O
the   O   O
connectome   O   O
where   O   O
the   O   O
ADD   SubstanceDisorder   O
group   O   O
demonstrated   O   O
significantly   O   O
less   O   O
connectivity   O   O
compared   O   O
with   O   O
the   O   O
CON   SubstanceDisorder   O
group   O   O
.   O   O
These   O   O
differences   O   O
in   O   O
connectivity   O   O
were   O   O
mostly   O   O
intra-hemispheric   O   O
(   O   O
55%   O   O
)   O   O
,   O   O
the   O   O
majority   O   O
(   O   O
38%   O   O
)   O   O
being   O   O
in   O   O
the   O   O
right   O   O
hemisphere   O   O
.   O   O
The   O   O
anatomical   O   O
distribution   O   O
of   O   O
these   O   O
connectivity   O   O
differences   O   O
between   O   O
the   O   O
two   O   O
groups   O   O
involved   O   O
frontal   O   O
(   O   O
insula   O   O
,   O   O
inferior   O   O
frontal   O   O
gyrus   O   O
,   O   O
orbitofrontal   O   O
cortex   O   O
)   O   O
,   O   O
limbic-associated   O   O
(   O   O
anterior   O   O
cingulate   O   O
gyrus   O   O
,   O   O
thalamus   O   O
)   O   O
,   O   O
and   O   O
striatal   O   O
(   O   O
accumbens   O   O
,   O   O
caudate   O   O
,   O   O
pallidum   O   O
)   O   O
regions   O   O
.   O   O
The   O   O
connectivity   O   O
differences   O   O
reported   O   O
in   O   O
this   O   O
ADD   SubstanceDisorder   O
sample   O   O
indicate   O   O
alterations   O   O
between   O   O
cognitive   O   O
,   O   O
striatal   O   O
and   O   O
limbic-associated   O   O
regions   O   O
during   O   O
reward   O   O
anticipation   O   O
that   O   O
persist   O   O
into   O   O
extended   O   O
abstinence   O   O
.   O   O
Highlights   O   O
Analytical   O   O
methods   O   O
can   O   O
capture   O   O
key   O   O
features   O   O
of   O   O
whole   O   O
brain   O   O
networks   O   O
in   O   O
addiction   O   O
.   O   O
We   O   O
compared   O   O
reward   O   O
network   O   O
connectivity   O   O
in   O   O
addiction   SubstanceDisorder   O
(   O   O
ADD   O   O
)   O   O
and   O   O
control   NoKnownDisorder   O
(   O   O
CON   O   O
)   O   O
groups   O   O
.   O   O
The   O   O
ADD   SubstanceDisorder   AddictionSeverityIndex
group   O   O
showed   O   O
disruptions   O   O
in   O   O
global   O   O
network   O   O
connectivity   O   O
.   O   O
Global   O   O
network   O   O
measures   O   O
may   O   O
be   O   O
more   O   O
sensitive   O   O
than   O   O
traditional   O   O
voxel-wise   O   O
analyses   O   O
.   O   O
The   O   O
prevalent   O   O
spatial   O   O
distribution   O   O
of   O   O
abnormalities   O   O
reported   O   O
in   O   O
cognitive   O   O
fMRI   O   O
studies   O   O
in   O   O
addiction   O   O
suggests   O   O
there   O   O
are   O   O
extensive   O   O
disruptions   O   O
across   O   O
whole   O   O
brain   O   O
networks   O   O
.   O   O
Studies   O   O
using   O   O
resting   O   O
state   O   O
have   O   O
reported   O   O
disruptions   O   O
in   O   O
network   O   O
connectivity   O   O
in   O   O
addiction   O   O
,   O   O
but   O   O
these   O   O
studies   O   O
have   O   O
not   O   O
revealed   O   O
characteristics   O   O
of   O   O
network   O   O
functioning   O   O
during   O   O
critical   O   O
psychological   O   O
processes   O   O
that   O   O
are   O   O
disrupted   O   O
in   O   O
addiction   O   O
populations   O   O
.   O   O
Analytic   O   O
methods   O   O
that   O   O
can   O   O
capture   O   O
key   O   O
features   O   O
of   O   O
whole   O   O
brain   O   O
networks   O   O
during   O   O
psychological   O   O
processes   O   O
may   O   O
be   O   O
more   O   O
sensitive   O   O
in   O   O
revealing   O   O
additional   O   O
and   O   O
widespread   O   O
neural   O   O
disturbances   O   O
in   O   O
addiction   O   O
,   O   O
that   O   O
are   O   O
the   O   O
provisions   O   O
for   O   O
relapse   O   O
risk   O   O
,   O   O
and   O   O
targets   O   O
for   O   O
medication   O   O
development   O   O
.   O   O
The   O   O
current   O   O
study   O   O
compared   O   O
a   O   O
substance   O   PolysubstanceAbuse
addiction   SubstanceDisorder   PolysubstanceAbuse
(   O   PolysubstanceAbuse
ADD   O   PolysubstanceAbuse
;   O   O
n   O   O
    O   O
=   O   O
    O   O
83   O   O
)   O   O
group   O   O
in   O   O
extended   O   O
abstinence   O   O
with   O   O
a   O   O
control   NoKnownDisorder   O
(   O   O
CON   O   O
;   O   O
n   O   O
    O   O
=   O   O
    O   O
68   O   O
)   O   O
group   O   O
on   O   O
functional   FunctionalMagneticResonanceImaging   O
MRI   FunctionalMagneticResonanceImaging   O
(   O   O
voxel-wise   O   O
activation   O   O
)   O   O
and   O   O
global   O   O
network   O   O
(   O   O
connectivity   O   O
)   O   O
measures   O   O
related   O   O
to   O   O
reward   O   O
anticipation   O   O
on   O   O
a   O   O
monetary   O   O
incentive   O   O
delay   O   O
task   O   O
.   O   O
In   O   O
the   O   O
absence   O   O
of   O   O
group   O   O
differences   O   O
on   O   O
MID   O   O
performance   O   O
,   O   O
the   O   O
ADD   SubstanceDisorder   O
group   O   O
showed   O   O
reduced   O   O
activation   O   O
predominantly   O   O
across   O   O
temporal   O   O
and   O   O
visual   O   O
regions   O   O
,   O   O
but   O   O
not   O   O
across   O   O
the   O   O
striatum   O   O
.   O   O
The   O   O
ADD   SubstanceDisorder   O
group   O   O
also   O   O
showed   O   O
disruptions   O   O
in   O   O
global   O   O
network   O   O
connectivity   O   O
(   O   O
lower   O   O
clustering   O   O
coefficient   O   O
and   O   O
higher   O   O
characteristic   O   O
path   O   O
length   O   O
)   O   O
,   O   O
and   O   O
significantly   O   O
less   O   O
connectivity   O   O
across   O   O
a   O   O
sub-network   O   O
comprising   O   O
frontal   O   O
,   O   O
temporal   O   O
,   O   O
limbic   O   O
and   O   O
striatal   O   O
nodes   O   O
.   O   O
These   O   O
results   O   O
show   O   O
that   O   O
an   O   O
addiction   SubstanceDisorder   O
group   O   O
in   O   O
extended   O   O
abstinence   O   O
exhibit   O   O
localised   O   O
disruptions   O   O
in   O   O
brain   O   O
activation   O   O
,   O   O
but   O   O
more   O   O
extensive   O   O
disturbances   O   O
in   O   O
functional   O   O
connectivity   O   O
across   O   O
whole   O   O
brain   O   O
networks   O   O
.   O   O
We   O   O
propose   O   O
that   O   O
measures   O   O
of   O   O
global   O   O
network   O   O
functioning   O   O
may   O   O
be   O   O
more   O   O
sensitive   O   O
in   O   O
highlighting   O   O
latent   O   O
and   O   O
more   O   O
widespread   O   O
neural   O   O
disruptions   O   O
during   O   O
critical   O   O
psychological   O   O
processes   O   O
in   O   O
addiction   O   O
and   O   O
other   O   O
psychiatric   O   O
disorders   O   O
.   O   O
Material   O   StatisticalMethod
and   O   StatisticalMethod
methods   StudyMethod   StatisticalMethod
Participants   O   StatisticalMethod
Sixty-eight   O   O
control   NoKnownDisorder   ControlSubject
(   O   O
CON   O   O
:   O   O
mean   O   O
age   O   O
39.79   O   O
    O   O
±   O   O
    O   O
1.22   O   O
;   O   O
18   O   O
females   O   O
,   O   O
50   O   O
males   O   O
)   O   O
and   O   O
83   O   O
addiction   SubstanceDisorder   AddictionSeverityIndex
(   O   O
ADD   O   O
:   O   O
mean   O   O
age   O   O
40.05   O   O
    O   O
±   O   O
    O   O
0.92   O   O
;   O   O
16   O   O
females   O   O
,   O   O
67   O   O
males   O   O
)   O   O
participants   O   PancreaticDisease
completed   O   O
the   O   O
current   O   O
study   O   O
.   O   O
The   O   O
current   O   O
dataset   O   O
was   O   O
collected   O   O
as   O   O
part   O   O
of   O   O
a   O   O
multi-centre   O   O
study   O   O
involving   O   O
three   O   O
study   O   O
sites   O   O
in   O   O
the   O   O
United   O   O
Kingdom   O   O
(   O   O
Imperial   O   O
College   O   O
London   O   O
,   O   O
University   O   O
of   O   O
Cambridge   O   O
and   O   O
University   O   O
of   O   O
Manchester   O   O
–   O   O
ICCAM   O   O
)   O   O
.   O   O
For   O   O
a   O   O
more   O   O
detailed   O   O
description   O   O
of   O   O
the   O   O
ICCAM   O   O
Platform   O   O
,   O   O
see   O   O
)   O   O
and   O   O
.   O   O
Inclusion   O   O
criteria   O   O
were   O   O
individuals   O   O
who   O   O
met   O   O
DSM-IV   O   O
measures   O   O
for   O   O
current   O   O
or   O   O
prior   O   O
substance   O   O
dependence   O   O
(   O   O
e.g   O   O
.   O   O
,   O   O
alcohol   O   O
,   O   O
cocaine   O   O
,   O   O
opiates   O   O
)   O   O
.   O   O
The   O   O
ADD   SubstanceDisorder   ParallelGroupTrial
group   O   ParallelGroupTrial
consisted   O   O
of   O   O
29   O   O
(   O   O
35%   O   O
)   O   O
pure   O   O
alcohol-dependent   O   O
,   O   O
42   O   O
(   O   O
50%   O   O
)   O   O
poly   O   O
substance-dependent   O   O
(   O   O
e.g   O   O
.   O   O
,   O   O
alcohol   O   O
and   O   O
cocaine   O   O
,   O   O
cocaine   O   O
and   O   O
opiate   O   O
)   O   O
and   O   O
12   O   O
(   O   O
15%   O   O
)   O   O
mono   O   GoNoGoTask
substance-dependent   O   O
(   O   O
e.g   O   O
.   O   O
,   O   O
cocaine   O   O
,   O   O
opiates   O   O
)   O   O
volunteers   O   O
.   O   O
While   O   O
addiction   O   O
studies   O   O
typically   O   O
recruit   O   O
volunteers   O   O
in   O   O
early   O   O
abstinence   O   O
,   O   O
there   O   O
was   O   O
no   O   O
upper   O   O
limit   O   O
in   O   O
the   O   O
current   O   O
study   O   O
.   O   O
The   O   O
mean   O   O
abstinence   O   O
length   O   O
from   O   O
alcohol   O   O
in   O   O
the   O   O
current   O   O
sample   O   O
was   O   O
15.00   O   O
    O   O
±   O   O
    O   O
3.50   O   O
    O   O
months   O   O
,   O   O
while   O   O
for   O   O
cocaine   O   O
and   O   O
opiates   O   O
it   O   O
was   O   O
27.99   O   O
    O   O
±   O   O
    O   O
3.72   O   O
and   O   O
39.04   O   O
    O   O
±   O   O
    O   O
7.75   O   O
    O   O
months   O   O
,   O   O
respectively   O   O
.   O   O
Therefore   O   O
,   O   O
the   O   O
current   O   O
ADD   O   O
group   O   O
was   O   O
made   O   O
of   O   O
a   O   O
heterogenous   O   O
sample   O   O
with   O   O
former   O   O
substance-dependencies   O   O
,   O   O
and   O   O
with   O   O
variable   O   O
levels   O   O
of   O   O
substance   O   O
abstinence   O   O
at   O   O
the   O   O
time   O   O
of   O   O
testing   O   O
.   O   O
This   O   O
meant   O   O
that   O   O
there   O   O
was   O   O
no   O   O
substance   O   O
dependence   O   O
measure   O   O
that   O   O
was   O   O
shared   O   O
by   O   O
all   O   O
members   O   O
of   O   O
the   O   O
ADD   SubstanceDisorder   O
group   O   O
.   O   O
The   O   O
CON   NoKnownDisorder   ParallelGroupTrial
group   O   ParallelGroupTrial
had   O   O
no   O   O
previous   O   O
history   O   O
of   O   O
substance   O   O
abuse   O   O
,   O   O
as   O   O
assessed   O   O
using   O   O
the   O   O
Alcohol   MentalHealthDiagnosisScale   BloodSubstanceMeasurement
,   MentalHealthDiagnosisScale   BloodSubstanceMeasurement
Smoking   MentalHealthDiagnosisScale   BloodSubstanceMeasurement
and   MentalHealthDiagnosisScale   BloodSubstanceMeasurement
Substance   MentalHealthDiagnosisScale   BloodSubstanceMeasurement
Involvement   MentalHealthDiagnosisScale   BloodSubstanceMeasurement
Screening   MentalHealthDiagnosisScale   BloodSubstanceMeasurement
Test   MentalHealthDiagnosisScale   BloodSubstanceMeasurement
(   MentalHealthDiagnosisScale   BloodSubstanceMeasurement
ASSIST   MentalHealthDiagnosisScale   BloodSubstanceMeasurement
)   MentalHealthDiagnosisScale   BloodSubstanceMeasurement
and   O   O
timeline   O   O
follow-back   O   O
.   O   O
All   O   O
participants   O   O
were   O   O
required   O   O
to   O   O
provide   O   O
a   O   O
negative   O   O
breath   O   O
alcohol   O   O
test   O   O
and   O   O
a   O   O
negative   O   O
urine   O   O
sample   O   O
for   O   O
various   O   O
drugs   O   O
of   O   O
abuse   O   O
on   O   O
the   O   O
day   O   O
of   O   O
testing   O   O
(   O   O
screening   O   O
for   O   O
the   O   O
presence   O   O
of   O   O
amphetamines   O   O
,   O   O
benzodiazepines   O   O
,   O   O
cannabinoids   O   O
,   O   O
cocaine   O   O
and   O   O
opiates   O   O
)   O   O
.   O   O
The   O   O
Mini-International   MentalHealthDiagnosisScale   BriefPsychiatricRatingScale
Neuropsychiatric   MentalHealthDiagnosisScale   BriefPsychiatricRatingScale
Interview   MentalHealthDiagnosisScale   BriefPsychiatricRatingScale
(   MentalHealthDiagnosisScale   BriefPsychiatricRatingScale
MINI   MentalHealthDiagnosisScale   BriefPsychiatricRatingScale
)   MentalHealthDiagnosisScale   BriefPsychiatricRatingScale
was   O   O
administered   O   O
to   O   O
all   O   O
participants   O   O
by   O   O
a   O   O
trained   O   O
psychiatrist   O   O
to   O   O
screen   O   O
for   O   O
the   O   O
presence   O   O
of   O   O
Axis   O   O
I   O   O
psychiatric   O   O
disorders   O   O
that   O   O
were   O   O
part   O   O
of   O   O
the   O   O
study   O   O
exclusion   O   O
criteria   O   O
.   O   O
Exclusion   O   O
criteria   O   O
included   O   O
1   O   O
)   O   O
current   O   O
use   O   O
of   O   O
regular   O   O
prescription   O   O
or   O   O
non-prescription   O   O
medication   O   O
that   O   O
could   O   O
not   O   O
be   O   O
stopped   O   O
;   O   O
2   O   O
)   O   O
current   O   O
primary   O   O
axis   O   O
I   O   O
diagnosis   O   O
,   O   O
past   O   O
history   O   O
of   O   O
psychosis   O   O
(   O   O
unless   O   O
drug-induced   O   O
)   O   O
;   O   O
3   O   O
)   O   O
current   O   O
or   O   O
past   O   O
history   O   O
of   O   O
enduring   O   O
severe   O   O
mental   O   O
illness   O   O
(   O   O
e.g   O   O
.   O   O
,   O   O
schizophrenia   O   O
,   O   O
bipolar   O   O
affective   O   O
disorder   O   O
)   O   O
;   O   O
4   O   O
)   O   O
other   O   O
current   O   O
or   O   O
past   O   O
psychiatric   O   O
history   O   O
that   O   O
,   O   O
in   O   O
the   O   O
opinion   O   O
of   O   O
a   O   O
psychiatrist   O   O
,   O   O
contraindicated   O   O
participation   O   O
;   O   O
5   O   O
)   O   O
history   O   O
or   O   O
presence   O   O
of   O   O
a   O   O
significant   O   O
neurological   O   O
diagnosis   O   O
that   O   O
may   O   O
have   O   O
influenced   O   O
the   O   O
outcome   O   O
or   O   O
analysis   O   O
of   O   O
the   O   O
results   O   O
;   O   O
6   O   O
)   O   O
claustrophobia   O   O
or   O   O
unable   O   O
to   O   O
lie   O   O
still   O   O
in   O   O
the   O   O
MRI   O   O
scanner   O   O
for   O   O
up   O   O
to   O   O
90   O   O
    O   O
min   O   O
and   O   O
7   O   O
)   O   O
presence   O   O
of   O   O
a   O   O
cardiac   O   O
pacemaker   O   O
,   O   O
other   O   O
electronic   O   O
device   O   O
or   O   O
other   O   O
MRI   O   O
contraindication   O   O
,   O   O
including   O   O
pregnancy   O   O
,   O   O
as   O   O
assessed   O   O
by   O   O
a   O   O
standard   O   O
pre-MRI   O   O
questionnaire   O   O
.   O   O
Secondary   O   O
or   O   O
lifetime   O   O
history   O   O
of   O   O
depression   O   O
or   O   O
anxiety   O   O
was   O   O
permitted   O   O
in   O   O
both   O   O
the   O   O
ADD   Abstinent   O
and   O   O
CON   NoKnownDisorder   O
groups   O   O
since   O   O
these   O   O
are   O   O
very   O   O
common   O   O
psychiatric   O   O
disorders   O   O
.   O   O
All   O   O
participants   O   O
provided   O   O
written   O   O
informed   O   O
consent   O   O
.   O   O
The   O   O
study   O   O
was   O   O
conducted   O   O
in   O   O
accordance   O   O
with   O   O
the   O   O
Declaration   O   O
of   O   O
Helsinki   O   O
.   O   O
Ethical   O   O
approval   O   O
was   O   O
obtained   O   O
from   O   O
West   O   O
London   O   O
and   O   O
Gene   O   O
Therapy   O   O
Advisory   O   O
Committee   O   O
National   O   O
Research   O   O
Ethics   O   O
Service   O   O
Committee   O   O
(   O   O
11   O   O
/   O   O
H0707   O   O
/   O   O
9   O   O
)   O   O
and   O   O
relevant   O   O
research   O   O
governance   O   O
and   O   O
Participant   O   O
Identification   O   AlcoholUseDisordersIdentificationTest
Centre   O   O
(   O   O
PIC   O   O
)   O   O
approvals   O   O
obtained   O   O
.   O   O
Monetary   O   MismatchNegativityTask
incentive   O   MismatchNegativityTask
delay   O   MismatchNegativityTask
task   O   MismatchNegativityTask
(   O   MismatchNegativityTask
MID   O   MismatchNegativityTask
)   O   MismatchNegativityTask
We   O   O
used   O   O
a   O   O
“   O   O
monetary   O   O
incentive   O   O
delay   O   O
task   O   O
”   O   Thing
(   O   O
MID   O   ExtrapyramidalDisease
)   O   O
,   O   O
which   O   O
was   O   O
based   O   O
on   O   O
that   O   O
originally   O   O
employed   O   O
by   O   O
Knutson   O   O
,   O   O
and   O   O
which   O   O
we   O   O
have   O   O
used   O   O
to   O   O
already   O   O
publish   O   O
data   O   O
from   O   O
the   O   O
ICCAM   O   O
platform   O   O
.   O   O
At   O   O
the   O   O
beginning   O   O
of   O   O
each   O   O
trial   O   O
,   O   O
participants   O   O
viewed   O   O
one   O   O
of   O   O
three   O   O
symbols   O   O
(   O   O
a   O   O
cue   O   O
)   O   O
that   O   O
indicated   O   O
the   O   O
potential   O   O
to   O   O
gain   O   O
fifty   O   O
pence   O   O
(   O   O
square   O   O
containing   O   O
an   O   O
ascending   O   O
arrow   O   O
)   O   O
,   O   O
lose   O   O
fifty   O   O
pence   O   O
(   O   O
square   O   O
containing   O   O
a   O   O
descending   O   O
arrow   O   O
)   O   O
or   O   O
experience   O   O
no   O   O
financial   O   O
outcome   O   O
(   O   O
square   O   O
containing   O   O
a   O   O
horizontal   O   O
line   O   O
-   O   O
here   O   O
referred   O   O
to   O   O
as   O   O
a   O   O
neutral   O   O
trial   O   O
)   O   O
.   O   O
Each   O   O
cue   O   O
was   O   O
presented   O   O
for   O   O
one   O   O
second   O   O
,   O   O
with   O   O
a   O   O
variable   O   O
duration   O   O
(   O   O
2   O   O
–   O   O
4   O   O
    O   O
s   O   O
)   O   O
for   O   O
the   O   O
subsequent   O   O
anticipation   O   O
period   O   O
.   O   O
Following   O   O
the   O   O
anticipation   O   O
period   O   O
,   O   O
participants   O   O
made   O   O
a   O   O
button   O   O
press   O   O
response   O   O
upon   O   O
the   O   O
presentation   O   O
of   O   O
a   O   O
visual   O   O
target   O   O
(   O   O
star   O   O
located   O   O
within   O   O
a   O   O
circle   O   O
)   O   O
.   O   O
Following   O   O
their   O   O
response   O   O
to   O   O
the   O   O
visual   O   O
target   O   O
,   O   O
participants   O   O
received   O   O
feedback   O   O
(   O   O
1.5   O   O
    O   O
s   O   O
)   O   O
as   O   O
to   O   O
whether   O   O
they   O   O
were   O   O
successful   O   O
(   O   O
“   O   O
Hit   O   O
”   O   O
)   O   O
or   O   O
unsuccessful   O   O
(   O   O
“   O   O
Miss   O   O
”   O   O
)   O   O
on   O   O
that   O   O
trial   O   O
and   O   O
saw   O   O
a   O   O
running   O   O
total   O   O
of   O   O
their   O   O
winnings   O   O
up   O   O
to   O   O
that   O   O
point   O   O
in   O   O
the   O   O
task   O   O
.   O   O
Following   O   O
feedback   O   O
,   O   O
there   O   O
was   O   O
an   O   O
end   O   O
fixation   O   O
period   O   O
(   O   O
3   O   O
–   O   O
5   O   O
    O   O
s   O   O
)   O   O
before   O   O
the   O   O
commencement   O   O
of   O   O
the   O   O
next   O   O
trial   O   O
.   O   O
Because   O   O
the   O   O
primary   O   O
objective   O   O
of   O   O
ICCAM   O   O
was   O   O
to   O   O
examine   O   O
the   O   O
neural   O   O
correlates   O   O
of   O   O
reward   O   O
anticipation   O   O
,   O   O
we   O   O
chose   O   O
to   O   O
use   O   O
a   O   O
smaller   O   O
number   O   O
of   O   O
loss   O   O
trials   O   O
in   O   O
order   O   O
to   O   O
amplify   O   O
the   O   O
incentive   O   O
salience   O   O
of   O   O
the   O   O
gain   O   O
trials   O   O
during   O   O
the   O   O
task   O   O
.   O   O
Consequently   O   O
,   O   O
there   O   O
was   O   O
a   O   O
total   O   O
of   O   O
18   O   O
gain   O   O
,   O   O
6   O   O
lose   O   O
and   O   O
18   O   O
neutral   O   O
trials   O   O
on   O   O
each   O   O
run   O   O
of   O   O
the   O   O
task   O   O
.   O   O
The   O   O
MID   O   O
task   O   O
was   O   O
tailored   O   O
to   O   O
adapt   O   O
to   O   O
the   O   O
visual   O   O
target   O   O
reaction   O   O
time   O   O
of   O   O
each   O   O
participant   O   O
by   O   O
using   O   O
a   O   O
staircase   O   O
algorithm   O   O
,   O   O
such   O   O
that   O   O
the   O   O
presentation   O   O
of   O   O
the   O   O
visual   O   O
target   O   O
became   O   O
shorter   O   O
as   O   O
performance   O   O
improved   O   O
during   O   O
the   O   O
experiment   O   O
.   O   O
This   O   O
enabled   O   O
us   O   O
to   O   O
set   O   O
a   O   O
limit   O   O
on   O   O
the   O   O
success   O   O
rate   O   O
of   O   O
each   O   O
participant   O   O
(   O   O
∼   O   O
66%   O   O
)   O   O
,   O   O
which   O   O
additionally   O   O
served   O   O
to   O   O
incentivize   O   O
participants   O   O
to   O   O
engage   O   O
in   O   O
the   O   O
task   O   O
.   O   O
Participants   O   O
were   O   O
instructed   O   O
to   O   O
maximize   O   O
their   O   O
winnings   O   O
and   O   O
were   O   O
told   O   O
they   O   O
would   O   O
receive   O   O
them   O   O
at   O   O
the   O   O
end   O   O
of   O   O
the   O   O
study   O   O
.   O   O
Dependent   O   O
measures   O   O
were   O   O
accuracy   O   O
(   O   O
percentage   O   O
)   O   O
and   O   O
mean   O   O
reaction   O   O
time   O   O
(   O   O
milliseconds   O   O
)   O   O
to   O   O
the   O   O
visual   O   O
target   O   O
on   O   O
each   O   O
of   O   O
the   O   O
gain   O   O
,   O   O
lose   O   O
and   O   O
neutral   O   O
trials   O   O
,   O   O
and   O   O
the   O   O
amount   O   O
won   O   O
(   O   O
£   O   O
)   O   O
on   O   O
the   O   O
task   O   O
.   O   O
Participants   O   O
completed   O   O
two   O   O
runs   O   O
of   O   O
the   O   O
task   O   O
(   O   O
432   O   O
    O   O
s   O   O
each   O   O
)   O   O
during   O   O
scanning   O   O
.   O   O
The   O   O
task   O   O
was   O   O
programmed   O   O
using   O   O
E-Prime   O   O
version   O   O
2.0   O   O
(   O   O
Psychology   O   O
Software   O   O
Tools   O   O
,   O   O
Pittsburgh   O   O
,   O   O
USA   O   O
)   O   O
.   O   O
Statistics   O   O
Group   O   O
demographics   O   O
were   O   O
compared   O   O
using   O   O
simple   O   O
independent   O   O
samples   O   O
t-test   O   O
analyses   O   O
.   O   O
For   O   O
analyses   O   O
conducted   O   O
on   O   O
MID   O   O
performance   O   O
,   O   O
two   O   O
(   O   O
Group   O   O
:   O   O
CON   O   O
vs   O   O
.   O   O
ADD   O   O
)   O   O
by   O   O
two   O   O
(   O   O
Condition   O   O
:   O   O
Gain   O   O
vs   O   O
.   O   O
Neutral   O   O
)   O   O
analyses   O   O
of   O   O
variance   O   O
were   O   O
conducted   O   O
.   O   O
The   O   O
CON   NoKnownDisorder   O
and   O   O
ADD   SubstanceDisorder   O
groups   O   O
were   O   O
also   O   O
compared   O   O
on   O   O
the   O   O
lose   O   O
accuracy   O   O
and   O   O
lose   O   O
reaction   O   O
time   O   O
performance   O   O
measures   O   O
,   O   O
as   O   O
well   O   O
as   O   O
the   O   O
amount   O   O
of   O   O
money   O   O
won   O   O
(   O   O
£   O   O
)   O   O
,   O   O
using   O   O
analyses   O   O
of   O   O
variance   O   O
.   O   O
These   O   O
analyses   O   O
were   O   O
conducted   O   O
controlling   O   O
for   O   O
study   O   O
site   O   O
.   O   O
For   O   O
the   O   O
graph   O   O
measures   O   O
(   O   O
see   O   O
below   O   O
)   O   O
we   O   O
conducted   O   O
two   O   O
(   O   O
Group   O   O
:   O   O
CON   O   O
vs   O   O
.   O   O
ADD   O   O
)   O   O
by   O   O
five   O   O
(   O   O
1   O   O
    O   O
⩽   O   O
    O   O
K   O   O
    O   O
⩽   O   O
    O   O
5   O   O
)   O   O
analyses   O   O
of   O   O
variance   O   O
,   O   O
while   O   O
also   O   O
controlling   O   O
for   O   O
study   O   O
site   O   O
.   O   O
All   O   O
these   O   O
analyses   O   O
were   O   O
conducted   O   O
using   O   O
permutation   O   O
testing   O   O
(   O   O
5000   O   O
iterations   O   O
)   O   O
in   O   O
the   O   O
R   O   O
statistical   O   O
software   O   O
package   O   O
(   O   O
www.R-project.org   O   O
)   O   O
.   O   O
Functional   FunctionalMagneticResonanceImaging   FunctionalImagingProtocol
MRI   FunctionalMagneticResonanceImaging   FunctionalImagingProtocol
(   FunctionalMagneticResonanceImaging   FunctionalImagingProtocol
fMRI   FunctionalMagneticResonanceImaging   FunctionalImagingProtocol
)   FunctionalMagneticResonanceImaging   FunctionalImagingProtocol
Data   O   O
acquisition   O   O
The   O   O
ICCAM   O   O
platform   O   O
was   O   O
designed   O   O
to   O   O
allow   O   O
the   O   O
rapid   O   O
testing   O   O
across   O   O
sites   O   O
of   O   O
multiple   O   O
compounds   O   O
relevant   O   O
to   O   O
addiction   O   O
treatment   O   O
.   O   O
Imaging   O   O
at   O   O
multiple   O   O
sites   O   O
in   O   O
parallel   O   O
on   O   O
the   O   O
ICCAM   O   O
platform   O   O
accelerated   O   O
study   O   O
completion   O   O
,   O   O
through   O   O
the   O   O
sharing   O   O
of   O   O
expertise   O   O
,   O   O
infrastructure   O   O
and   O   O
capacity   O   O
.   O   O
    O   O
For   O   O
a   O   O
more   O   O
comprehensive   O   O
description   O   O
of   O   O
data   O   O
acquisition   O   O
across   O   O
the   O   O
three   O   O
sites   O   O
on   O   O
ICCAM   O   O
,   O   O
please   O   O
see   O   O
McGonigle   O   O
et   O   O
al   O   O
.   O   O
Briefly   O   O
,   O   O
all   O   O
centres   O   O
operated   O   O
MRI   O   PrimaryOutcome
machines   O   PrimaryOutcome
with   O   O
a   O   O
main   O   O
magnetic   O   O
field   O   O
of   O   O
3   O   O
    O   O
T   O   O
(   O   O
T   O   O
)   O   O
.   O   O
Centres   O   O
in   O   O
London   O   O
and   O   O
Cambridge   O   O
operated   O   O
nominally   O   O
identical   O   O
3   O   O
    O   O
T   O   O
Siemens   O   O
Tim   O   O
Trio   O   O
systems   O   O
running   O   O
the   O   O
syngo   O   O
MR   O   O
B17   O   O
software   O   O
with   O   O
a   O   O
Siemens   O   O
32   O   O
channel   O   O
receive-only   O   O
phased-array   O   O
head   O   O
coil   O   O
.   O   O
The   O   O
Manchester   O   O
centre   O   O
operated   O   O
a   O   O
3   O   O
    O   O
T   O   O
Philips   O   O
Achieva   O   O
running   O   O
version   O   O
2.6.3.5   O   O
software   O   O
and   O   O
an   O   O
8   O   O
element   O   O
SENSE   O   O
head   O   O
coil   O   O
.   O   O
